20112012
corporate
responsibility
update

for more than
ecatur           etureli lilly
              136 years
            unt
                                          contents


abo   cum nis
and company    has demonstrated a         01
                                          message from the ceo	                                 03

nullectia        in rest
commitment to being   a responsible       about lilly
                                          key performance indicators
                                                                                                05
                                                                                                06

ut  vellum
global           qui
       citizenincluding  a long          02

blaborectat
                                          conducting our business ethically and transparently   07

history of philanthropic contributions   03
cusam
our greatestoccul
              contribution to society
                                          enhancing access to medicines                         13


                                          04
however is discovering and developing    developing innovative medicines                       19


                                          05
innovative medicines while running        supporting strong workplace practices                 30


                                          06
our business ethically and responsibly   lilly around the world                                38


                                          07
                                          engaging with patients                                41


                                          08
                                          fostering environmental sustainability                44


                                          09
                                          united nations global compact index                   58
                                          about this report                                     59

                      lorem ipsum
                      message from the ceo

                      01          02          03          04            05       06         07          08         09




message from the ceo
dear reader                                                       we also provide opportunities for our employees to
                                                                   share their expertise with communities around the
at the core of lillys vision is our aim to improve global
                                                                   world connecting hearts abroad our signature global
health in the 21st century we do this first and foremost
                                                                   service initiative is one example launched in 2011
by creating medicines that help people live longer
                                                                   this program sends 200 lilly ambassadors each year
healthier more active lives but we also believe that how
                                                                   on twoweek community development assignments in
we do business is as important as what we do lillys
                                                                   asia africa and central and south america
commitment to the united nations global compact
ungc reflects the core values of integrity excellence          lilly ranks among the worlds most charitable companies
and respect for people that have been integral to our              donating more than 590 million in 2011 but when cr is
company since our founding more than 136 years ago                only about charity we believe its an opportunity missed
                                                                   we know we can do even more to improve global health
were proud to present this update report to highlight
                                                                   if we bring to the table our expertise in chronic diseases
our commitments to and progress around corporate
                                                                   along with our financial resources
responsibility cr
                                                                   increasingly we are integrating the concept of shared
for us responsibility starts with how we treat our
                                                                   value into the way we operate using our business
employees our employees play an indispensable role
                                                                   expertise to help address pressing social needs opens
in helping us to meet our cr commitments in turn we
                                                                   up new opportunities for us to provide solutions to health
strive to encourage them by maintaining a supportive
                                                                   challenges the world over we believe this approach will
and respectful working environment we put special
                                                                   help to create enduring value for society and for lilly
emphasis on flexibility in the workplace and we were
                                                                   by making individual patients better we help those
honored to have been named as diversityincs top
                                                                   patientsas well as their communities and broader
company for working families in 2012
                                                                   societiesto thrive




     03               lilly 20112012 corporate responsibility update

                      lorem ipsum
                      message from the ceo

                      01          02          03          04            05         06           07            08      09




along with investing our own assets and expertise we              for example at our speke united kingdom manufacturing
spearhead broad strategic partnerships to improve                 facility new processes for antibiotic production have
access to health care for example                                decreased water usage by 143 million liters per yearor
                                                                   about 10 percent of the total usagewhile reducing steam
 the lilly mdrtb partnership offers education
                                                                   usage by 7000 metric tonsor 5 percent of overall use
  training and improved care to people fighting deadly
                                                                   these changes helped save more than 560000 in 2012
  multidrugresistant tuberculosis
                                                                   projected waste stream reductions related to the initiative
 the lilly ncd partnership launched in 2011 will                could push annual savings to 2 million were also
  provide 30 million over five years to fight the rising          pleased that in 2011 10 lilly sites globally reported
  burden of noncommunicable diseases ncds in                    zero landfill status indicating that they send less than
  developing nations                                              05 percent of generated waste to landfill
 in 2011 we announced lilly truassist an easytouse
                                                                   were very proud of these and other accomplishments yet
  onestop resource about the patientassistance
                                                                   we recognize that we must make further progress still and
  programs that lilly has long offered to help people
                                                                   we are committed to doing just that on behalf of everyone
  obtain the lilly medications they need more than
                                                                   at lilly thank you for your interest in our company and in
  250000 patients received help through these programs
                                                                   this cr update we welcome your feedback
  in 2011a 12 percent increase from the previous year
in the environmental arena weve set goals to limit
our impacts drawing on our scientific technical and
business expertise to eliminate waste and inefficiencies
wherever possible


                                                                   john c lechleiter phd
                                                                   chairman president and chief executive officer

                                                                   november 30 2012




     04               lilly 20112012 corporate responsibility update

                      loremlilly
                      about ipsum

                      01          02          03          04            05         06          07       08         09




about lilly                                                                  facts at a glance
                                                                             as of november 2012
at lilly we make medicines that help people live longer
healthier more active lives founded in 1876 we are
the 10th largest pharmaceutical company in the world

                                                                             136                        7400                      55                         8
around the globe we have forged productive alliances
and partnerships that advance our capacity to develop
innovative medicines at lower costs for some of the
worlds most urgent medical needs                                           years strong founded on   employees engaged in       countries where clinical   countries with research
                                                                             may 10 1876               research and development   research is conducted      and development facilities
lilly has a long history of medical innovation most notably
in the treatment of infectious diseases diabetes and
depression today our portfolio also includes oncology
and biomedicines and our emerging markets business
unit works to deliver medicines to address unmet needs
around the world for additional information about our                       125                        242                      usa                        lly
corporate history and significant medical breakthroughs
visit the about section of wwwlillycom                                  countries where            billion in worldwide       headquartered in           symbol listed on the
                                                                             products are marketed      revenue in 2011            indianapolis indiana     new york stock exchange
                                                                                                                                   united states
about elanco
elanco is a division of lilly that focuses on animal
wellbeing animal productivity and food safety in more
than 75 countries the company introduced its first product
for veterinary use in 1953 and today offers more than
                                                                             13                         38000
30 products elanco employs more than 2700 people
                                                                             countries with             employees worldwide
worldwide with offices in more than 40 countries its
                                                                             manufacturing plants
global headquarters is in greenfield indiana united states
which is also the base of its us business operations
elanco products are marketed primarily to cattle poultry
and swine producers elanco companion animal health
develops pet medicines and assists veterinarians in helping
companion animals lead longer healthier lives




     05               lilly 20112012 corporate responsibility update

                           lorem
                           key   ipsum
                               performance indicators

                           01           02           03              04      05           06           07            08           09




key performance indicators

                                                                              goal             2007         2008          2009         2010        2011    1
                                                                                                                                                               2013 goal 2007 baseline for all three workplacerelated
                                                                                                                                                               metrics some health and safety data from prior years were
financial highlights                                                                                                                                           adjusted slightly due to updated data collection

worldwide revenue  millions                                                           186335     203719    218360    230760    242865
                                                                                                                                                           2
                                                                                                                                                               following world resources institute wri guidance progress
                                                                                                                                                               toward environmental goals is reported on an adjusted basis
research and development  millions                                                      34867      38409     43265     48842     50208       accounting for mergers acquisitions and divestitures as
                                                                                                                                                               appropriate to ensure comparability unless stated otherwise
                                                                                                                                                           3
                                                                                                                                                               2013 goal 2007 baseline
workplace highlights1                                                                                                                                      4
                                                                                                                                                               2013 goal 2007 baseline this goal covers lillys scope 1
                                                                                                                                                               and scope 2 emissions
serious injury rate per 100 employees                                       50             144         118         092         096         109
                                                                                                                                                           5
                                                                                                                                                               2013 goal 2010 baseline lilly established this goal after
losttime injury rate per 100 employees                                     50             062         059         038         041         047       meeting its prior goalto reduce water intake in absolute
                                                                                                                                                               terms by 25 percent by 2013 compared to 2007four years
motorvehicle collision rate collisions per million miles driven            50            1110        1206        1117        1048        1028       early water intake as used in evaluating our progress
                                                                                                                                                               toward our waterreduction goal is the total amount of
                                                                                                                                                               water coming into a facility including water pumped
philanthropy highlights                                                                                                                                        from bodies of surface water and groundwater and water
                                                                                                                                                               provided by a utility it includes water used in processes
product and other inkind donations  millions                                               240         297          335         373        549        utilities and other ancillary operations such as irrigation
                                                                                                                                                               the term does not include groundwater pumped solely for
cash contributions  millions                                                                 75          53           70          57         48        treatment to satisfy regulatory actions or requirements
                                                                                                                                                               eg remediation activities where the water is not used for
total contributions  millions                                                               315         350          405         430        597        another purpose values do not include the water extracted
                                                                                                                                                               from wells solely for the purpose of lowering the groundwater
                                                                                                                                                               tables to maintain the physical and structural integrity
environmental highlights2                                                                                                                                      of building foundations water intake values for 2010 were
                                                                                                                                                               adjusted from previously reported values due to metering
energy consumption million btus                                                        12900000    11900000   11300000   11200000   10800000       data evaluations at one of our top water use sites
energy intensity thousand btussquare foot                                  153            594          562           543          520         495
                                                                                                                                                           6
                                                                                                                                                               2013 goal 2010 baseline lilly established this goal after
                                                                                                                                                               meeting its prior goalto reduce waste to landfills by 40
greenhouse gas emissions scope 1 and scope 2 metric tons co2e                         1810000     1730000    1640000    1600000    1530000       percent in absolute terms by 2013 compared to 2007four
                                                                                                                                                               years early lillys former and current wastetolandfill
greenhouse gas emissions intensity metric tons co2e1000 square feet       15  4
                                                                                                833         822         782         745         700       goals do not include construction and demolition debris
                                                                                                                                                               biosolids from wastewater treatment plants incinerator
water intake billion liters                                                     5
                                                                                     5
                                                                                                196         176         132         128         133       ash coal ash if reused for mine reclamation or road base
                                                                                                                                                               and mycelia and urea reused for fertilizer unlike our
water intensity million litersmillion  revenue                                              105        0864       0605        0555        0549        energy greenhouse gas emissions and waterintake
                                                                                                                                                               goals performance data used to calculate progress
waste generation metric tons                                                             379000       387000      287000      228000      242000        against our wastetolandfill goal do not exclude data
waste generation intensity metric tonsmillion  revenue                                      203         190         131         988         107       from our tippecanoe laboratories facility in indiana
                                                                                                                                                               united states which lilly divested in 2009 because the
waste to landfill metric tons                                               206        32000        22300       14800       15900       10900        data at that site did not have a significant impact on our
                                                                                                                                                               worldwide wastetolandfill total
reportable permitlimit exceedances     7
                                                                                                 43           27            16           11           8    7
                                                                                                                                                               reportable permitlimit exceedances are environmental
                                                                                                                                                               releases to air water or land outside of regulatory limits these
                                                                                                                                                               do not necessarily result in harm to people or the environment




       06                  lilly 20112012 corporate responsibility update

                 conducting our business ethically and transparently

     01         02           03          04            05        06    07   08   09




                                                                                      02

                                                                                      conducting
                                                                                      our business
                                                                                      ethically and
                                                                                      transparently
                                                                                      here at lilly our actions are grounded
                                                                                      in our core company values of integrity
                                                                                      excellence and respect for people how
                                                                                      we do business is as important as what we
                                                                                      do we strive to be a leader in corporate
                                                                                      responsibility we demonstrate our values
                                                                                      through responsible business practices
                                                                                      that reflect our commitments to strong
                                                                                      governance principles transparency
                                                                                      patient customer and employee privacy
                                                                                      ethical product promotion and stakeholder
                                                                                      engagement our participation in the
                                                                                      public policy process also demonstrates
                                                                                      our values and affects how we do business



07   lilly 20112012 corporate responsibility update

                                 conducting our business ethically and transparently

                     01         02           03          04            05        06        07          08          09




acting with integrity
our commitment to ethics and compliance is born of                lillys global anticorruption program a component          summarizes key principles from global company policies
our commitment to integrity our policies our code of            of our overall gecp includes policies and procedures        and provides examples for employees to practice applying
business conduct which we call the red book  our             tailored to the challenges of ensuring compliance in         these principles to their decisions and actions the red
compliance management systems and our training                   the 125 countries in which we market our products we        book is designed to provide foundational guiding principles
programs reinforce ethical behavior                              have implemented a global anticorruption program            to help our employees navigate an increasingly complex
                                                                  in every lilly affiliate worldwide internally we require   global business environment
as a global leader in the development manufacture and
                                                                  training for our employees on anticorruption issues
sale of pharmaceutical products we have implemented                                                                          the red book is amplified by policies standards and
                                                                  including bribery
and we continue to refine and improveprograms                                                                                 procedures accessible to employees on the companys
designed to promote ethical conduct and instill a culture         our chief executive officer routinely sets the tone at      intranet these documents govern lillys actions with
of compliance we train all of our employees in ethical           the top by speaking directly to employees about ethics      respect to specific areas including anticorruption
business practices and have systems in place to detect            and compliance issues through his blog through audio        privacy product promotion safety medical research
potential violations of the law and company policies             and video messages and through global town hall           communications securities trading record keeping
                                                                  employee meetings                                           international transactions ethical interactions with
our global ethics and compliance program gecp takes
                                                                                                                               external parties interactions with government and public
a comprehensive approach to compliance it includes
training and communications designed to prevent potential         code of conduct policies standards                        officials payments grants and donations meetings with
                                                                  and procedures                                               healthcare providers gifts product samples and many
issues from arising as well as reporting auditing and
                                                                                                                               other topics
monitoring to detect potential compliance failings we            our ethics and compliance programs include polices
have invested significant resources in our formal ethics          standards and procedures we communicate our key            more detailed information about our compliance
and compliance programs which include focused efforts            compliancerelated expectations through a variety of         policies and practices can be found in our 2010 corporate
on privacy anticorruption and appropriate product              vehicles including the red book this document which       responsibility report
promotion among other areas                                     is available in 24 languages emphasizes the companys
                                                                  values and the importance of ethical decisionmaking




     08              lilly 20112012 corporate responsibility update

                                 conducting our business ethically and transparently

                     01         02           03          04            05        06         07          08          09




advancing public policy                                                                                                         transparency at lilly
at lilly we are committed to helping people live longer         new pricing models                                            experience has taught us that transparency
healthier more active lives to fulfill our mission we
                                                                  the pharmaceutical industrys business model has              in our operations can help to build trust
believe it is important to ensure that patients have access
                                                                  become increasingly challenged payers policymakers
to needed medications lilly participates in public policy                                                                      with our stakeholders we believe that
                                                                  and patients who pay out of pocket often believe the
debates around the world and contributes to the policy                                                                          transparency regarding business practices
                                                                  prices for newer medicines are too high at the same
environment in a manner that supports patient access
                                                                  time companies that discover and develop these new           that involve financial payments to physicians
to innovative medicinesleading to improved patient
                                                                  medicines are experiencing unprecedented price erosion        helps to build trust with the public in 2004
outcomes since 2010 we have updated our position on
                                                                  through legislated price cuts inappropriate reference
differential pricing and have supported research that                                                                           we were the first company to announce
                                                                  pricing and other restrictions on physician and patient
contributes to policy efforts centered on patient access                                                                        that we would voluntarily disclose to the
                                                                  choice wealthier countries that can afford innovative
to innovative medicines
                                                                  medicines are increasingly unwilling to pay for thema        public our us clinicaltrial resultseven
                                                                  situation exacerbated by the global financial crisiswhile    unfavorable ones we were also the first
differential pricing                                              developing countries cannot afford these innovative
                                                                  medicines at developedmarket prices
                                                                                                                                company to report the results of a thirdparty
this term refers to a set of policies that enables
differential pricing of medicines within a country and                                                                          audit of our database in addition we publicly
                                                                  new pricing approaches are needed that both promote
that achieves variable prices based on a patients ability
                                                                  access to medicines by countries in varying stages
                                                                                                                                report the funding we provide in the united
to pay in order to balance the desire to have affordable                                                                        states to institutions in the form of educational
                                                                  of development and reward innovative research
prices for lowincome populations while simultaneously
                                                                  and development because so many of the barriers              grants and charitable contributions our
rewarding medical advances with competitive market
                                                                  to accessing medicines in the developing world are            financial support to patient organizations
prices this approach facilitates access to medicines
                                                                  associated with public policy issues lilly engaged a
and supports continued research and development
                                                                  number of leading academics to explore this topic with
                                                                                                                                based in europe our financial payments
which benefits patients public and private payers and                                                                         to us healthcare professionals who are
                                                                  the resulting research published in the journal health
the pharmaceutical industry to be effective differential
                                                                  affairs the outcome of this effort informs our own           contracted as speakers for educational pro
pricing must be supported by an environment that is
                                                                  policy engagement with global health stakeholders             grams and who provide us with advice and
free of reference pricing a strategy that establishes a
                                                                  and we hope will help foster continued dialogue on the
products price point by benchmarking the price of the
                                                                  topic the resulting research was published in health
                                                                                                                                our companys annual political contributions
same product in other countries and that prevents the
                                                                  affairs health affairs 30 no 8 2011 and health affairs
diversion of discounted medicines to higherpriced markets
                                                                  29 no12 2010




     09              lilly 20112012 corporate responsibility update

                                 conducting our business ethically and transparently

                     01         02           03          04              05              06              07               08              09




                                                                     managing our supply chain




50             
                                                                     at lilly we manage our supply chain to help maintain a                                   supporting the pharmaceutical supply
                                                                     safe and uninterrupted supply of our medicines within                                    chain initiative
                                                                     our own operations and the broader pharmaceutical
                                                                                                                                                               in early 2009 lilly adopted the pharmaceutical industry
                                                                     industry we work to support the united nations global
                                                                                                                                                               principles for responsible supply chain management
                                                                     compact principles ensure adherence to labor laws and
                                                                                                                                                               as set forth by the pharmaceutical supply chain initiative
                                                                     protect the environment we partner with our suppliers
of api active pharmaceutical ingredient products                                                                                                             psci an industry group in which lilly is an active
                                                                     around the world to encourage them to adopt the same
were manufactured at lillyowned facilities                                                                                                                    participant psci principles were designed to align with
                                                                     global leadership standards that we have set for ourselves
                                                                                                                                                               the principles of the united nations global compact




14
                                                                                                                                                               they represent highlevel expectations set for industry
                                                                     lillys supply chain at a glance                                                          suppliers in the areas of ethics labor health and safety
                                                                     lilly maintains relationships with thousands of suppliers                                 the environment and related management systems
                                                                     of materials and services we categorize suppliers into                                   upon adopting the principles lilly revised and updated
                                                                     three tiers which help to identify their type of impact from                             our supplier code of conduct to reflect these principles
                                                                     a supply risk perspective8                                                               to view the current lilly supplier code of conduct
number of pharmaceutical companies                                                                                                                            visit wwwsupplierportallillycomsupplierspages
                                                                     in 2012 approximately half of our api active pharmaceutical
including lilly with a shared goal of providing                                                                                                               conductcodeaspx
                                                                     ingredient products were manufactured at lillyowned
suppliers and service providers with common                          facilities including three sites in the united states as well                           through our participation in the psci lilly is proud to
health and safety environmental labor ethics
                                                                     as sites in ireland puerto rico and the united kingdom                                 stand alongside 13 other pharmaceutical companies that
and business management standards
                                                                     finishing operations including labeling and packaging                                   share a goal of providing suppliers and service providers
                                                                     take place at a number of sites throughout the world                                     with common health and safety environment labor ethics
                                                                                                                                                               and business management standards together with
                                                                                                                                                               our industry peers we are working to educate suppliers
                                                                                                                                                               and ensure that our partners operate in a way that is
                                                                                                                                                               consistent with our own company values




                                                                 8
                                                                     supply risk is the risk associated with lillys dependence on a third party for either services or materials that are critical to the operation of our business supply
                                                                     risk can come from many factors including but not limited to supplier financial stability ability to produce or provide services in a quality manner or the impact
                                                                     of a natural disaster on the suppliers site this risk is monitored on an annual basis and mitigation plans are implemented and monitored to minimize it




     10              lilly 20112012 corporate responsibility update

                                    conducting our business ethically and transparently

                       01          02           03          04           05         06        07           08         09




lilly fully embraces the psci vision that through the               as part of lillys ongoing supply chain risk management             lilly suppliers by type
application of the principles better social economic and         lilly suppliers in tiers b and c must complete an annual
environmental outcomes will result for those involved in            supplier selfassessment questionnaire and be available              tier a
the pharmaceutical supply chain this includes improved             for audits at lillys discretion in 2011 together with the        suppliers provide goods and services across a range
conditions for workers expanded economic development              other psci companies lilly began exploring the best way             of areas needed for general office functioning this
and a cleaner environment for local communities as a               to ensure and monitor compliance among suppliers and                includes general office supplies travel services it
member of the psci lilly is committed to influencing               began conducting supplier audits this work is ongoing               equipment catering and other routine services
positive social and environmental change in the pharma             and will be reported on in more depth in our next report
ceutical industry and we will work to build our suppliers                                                                              tier b
capabilities in these areas                                        supplier diversity                                                   suppliers provide raw materials and other common
                                                                                                                                         commodities used for packaging and manufacturing
to learn more about lillys management of environmental             lilly also aspires to broaden the participation of small             operations this includes packaging materials waste
impacts throughout our supply chain see the fostering              and diverse businesses in our supplier base since 2005             disposal services and energy
environmental sustainability section beginning on page 44         the us small business administration has recognized
                                                                    lilly as outstanding in our efforts to promote and                 tier c
upholding human rights                                              maintain supplier diversity our goal is to achieve greater          suppliers provide active pharmaceutical ingredients
                                                                    than 10 percent of our external spend with small and                 including specialty chemicals suppliers in this tier
lilly maintains a longstanding practice of complying
                                                                    diverse suppliers in 2011 we spent 522 million with               include active ingredient suppliers contract manu
with local minimumage laws and requirements and
                                                                    diverse suppliers exceeding our goal of 430 million                facturers and research and development labs
does not employ child labor or forced or compulsory
                                                                    in diversesupplier spending
labor in any of our facilities globally in 2011 lilly began
revising our global standards and procedures to include
specific language about human rights                                                                                                                                                            4


                                                                                                                                           95

                                                                                                                                                                                                 1

                                                                                                                                    		
                                                                                                                                         supplier data includes data for elanco our animal health division




                                                                                                                                                         tier c
                                                                                                                                                              1
                                                                                                                                                                    tier b
                                                                                                                                                                         4
                                                                                                                                                                                tier a
                                                                                                                                                                                     95
      11               lilly 20112012 corporate responsibility update

                                             conducting our business ethically and transparently

                              01             02             03             04             05             06             07      08       09




fighting counterfeit medicines                                                                                                                         at the european alliance for
what ranks among the biggest supply chain concerns                                    criminals are drawn to pharmaceutical counterfeiting by           access to safe medicines we are
for an international pharmaceutical company like lilly                               the prospect of high profits and low risk as offenders are       raising public awareness of the
protecting the public from counterfeit medicines with                                rarely prosecuted because of its unregulated environment
global sales last year estimated as high as 200 billion9                            full anonymity and access to patients the internet is a         dangers posed by counterfeit
counterfeit medicine is big business and it is growing                              hot spot for counterfeiters criminal organizations dupe          medicines available in the
in every part of the world patients are unknowingly                                  customers into buying counterfeit medicines through fake
encountering counterfeits that look just like the actual                              online pharmacies which use images of trademarked              legitimate supply chain and over
medicine from the appearance of the package to the                                   or branded pharmaceutical products                               the internet as we undertake
size and color of the pill these are dangerous imposters
that may contain inactive and useless ingredientsor
                                                                                      lilly is actively engaged in efforts to combat counterfeiting    major projects each year lillys
                                                                                      and we partner with governments and others to protect
even toxic substances such as arsenic in every case
                                                                                      the health and safety of patients who take our medicines         muchvalued support helps bring
counterfeits are unreliable in some cases they can
cause harm to patients including death
                                                                                      lilly is a founding member and steering group participant         our message to wider audiences
                                                                                      of the alliance for safe online pharmacies a broad coalition
counterfeit medicines pose a real and growing threat                                  of stakeholders who have an interest in protecting patient        and effect real change we are
to patient safety and worldwide public health pharmaceutical                         safety and ensuring patient access to safe and legitimate         tremendously proud to have lilly
counterfeiting crosses geographic boundaries and affects                              online pharmacies in europe lilly is active in the european
patients suffering from a variety of diseases medicines                              alliance for access to safe medicines to further patient          stand shouldertoshoulder with
commonly involved in counterfeiting include those used                                education about the dangers of counterfeit medicine              us in this important work
for erectile dysfunction oncology cardiovascular disease
and mental health preventing the proper treatment of
these conditions
                                                                                                                                                       jim thomson
                                                                                                                                                       chair european alliance for access to safe medicines




 9
     source world economic forum global risks 2011 sixth edition an initiative of the risk response network january 2011




         12                   lilly 20112012 corporate responsibility update

                             enhancing access to medicines

     01          02         03
                            03           04            05    06   07   08   09




                                                                                 03

                                                                                 enhancing
                                                                                 access to
                                                                                 medicines
                                                                                 around the world its estimated that
                                                                                 at least a billion people lack access to
                                                                                 comprehensive health care including
                                                                                 medicines and other treatment tools
                                                                                 lilly is committed to expanding access to
                                                                                 medicines and health care and we work
                                                                                 with partners to improve health outcomes
                                                                                 for people in need we are putting a special
                                                                                 focus on improving the health of people
                                                                                 in low and middleincome countries
                                                                                 around the globespecifically by tackling
                                                                                 several tenacious diseasestuberculosis
                                                                                 and diabetesthat are growing rapidly
                                                                                 in these parts of the world




13   lilly 20112012 corporate responsibility update

                                              enhancing access to medicines

                      01          02          03
                                              03          04            05         06         07          08          09




our approach to expanding                                                                                                        the business community can
access to medicines                                                                                                               and mustplay a vital role in
lilly is committed to taking thoughtful steps to meaning          for a map of these countries visit wwwlillycom            addressing complex problems
fully enhance access to medicines and improve health               responsibilityaccesstomedicinespagesincreasing
for underserved populations however we realize that no           accesstomedicinesaspx
                                                                                                                                  its clear that writing a check or
single organization can solve all of the problems related                                                                         donating product alone doesnt
to access to medicines therefore we focus our efforts
                                                                                                                                  have a lasting impact a growing
where we believe we can have the greatest impact                  truassist
                                                                                                                                  body of evidence demonstrates
pricing our medicines                                              at lilly were dedicated to discovering and developing
                                                                                                                                  that when a company engages
                                                                   innovative medicines that help improve peoples lives this
lilly strives to engage with governments throughout the
world to offer our products at sustainable prices that
                                                                   commitment includes offering assistance to people who may      with partners in an area in which
                                                                   not be able to afford our medicines in 2011 we announced
are affordable for local populations prices for prescription                                                                     the company has deep expertise
                                                                   lilly truassist an easytouse onestop resource about
medicines like other products can differ from country
to country because of differences in currency value and
                                                                   how to access lillys existing patientassistance programs    and a vested interest society
market dynamicsor they may be kept artificially low                                                                              benefits and the company
by government price controls lilly advocates for policies
that support differential pricingie the charging of
                                                                        lilly participates in the partnership for prescription    enhances its own performance
different prices based on a purchasers ability to pay                 assistance pparx the pharmaceutical industrys
to learn more about our work in this area see page 09                 program to make it easier for physicians and             john c lechleiter phd
                                                                        patients to access patientassistance programs          lilly chairman president and chief executive officer
patents in least developed countries
in many developing countries lilly does not seek nor              more than 250000 patients received help through
enforce patents for our medicines to further contribute to        these programs in 2011a 12 percent increase from
making these medicines more accessible for example               the previous year the program covers a range of
lilly does not seek patents in least developed countries           health conditions including mental health diabetes
ldcs as defined by the united nations as a result             cardiovascular disease mens health osteoporosis
generics manufacturers are free to produce and provide             oncology and growthhormone disorders the market
generic versions of our medicines in these countries              value of the assistance provided through this program
                                                                   totaled more than 500 million




     14               lilly 20112012 corporate responsibility update

                                         enhancing access to medicines

                01           02          03
                                         03          04            05    06   07   08   09




the lilly global health
innovation campaign
lilly is committed to partnering closely with local
governments and organizations to identify and promote
healthcare solutions that reduce the burden of diabetes
and multidrugresistant tuberculosis mdrtb

in 2011 we unveiled the lilly global health innovation
campaign aimed at improving health for underserved
populations the campaign encompasses two of lillys
signature programs the lilly ncd partnership and the
lilly mdrtb partnership to create positive longterm
change lilly together with our partners is focused on
researching
piloting new models of health care based on sophisticated
research and detailed data collection that immediately
benefit patients

reporting
sharing data and lessons learned locally and globally

advocating
informing key stakeholders about program findings
and encouraging the adoption of proven solutions




   15            lilly 20112012 corporate responsibility update

                                             enhancing access to medicines

                     01          02          03
                                             03          04            05       06          07          08         09




the lilly ncd partnership                                                                                                        noncommunicable diseases are
noncommunicable diseases ncds also known as                   mexico                                                          afflicting nations communities
chronic diseases include cardiovascular diseases                in mexico lilly works with the carlos slim health institute    and families around the world
diabetes cancer and chronic respiratory diseases in            to evaluate and enhance casalud its worldclass primary
developing countries these diseases havent garnered             care clinic training program centered on comprehensive         with the most vulnerable bearing
the same attention that tuberculosis hivaids and               ncd diagnosis and care lillys role is to research the         most of the burden
malaria have yet together ncds account for some 63             program to demonstrate how casalud has increased the
percent of all deaths worldwide and fourfifths of these         number of diagnosed patients andby ensuring early
                                                                  interventions are in placehas improved and prolonged
                                                                                                                                 john c lechleiter phd
deaths occur in low and middleincome countries
                                                                  lives we will also be measuring the cost benefit to early     lilly chairman president and chief executive officer
thats why lilly created the lilly ncd partnership a 30
million commitment over five years to fight the growing           diagnosis and management of diabetes and sharing this
burden of noncommunicable diseases through research             data with other programs
reporting and advocacy
                                                                  south africa
no company government or single institution will
                                                                  in johannesburg africas secondlargest city lilly
solve the ncd challenge alone it will take new ways
                                                                  is working with project hope to establish the hope
of thinking and collaboration on an unprecedented
                                                                  centre a fiveyear communitybased project that will
scale designed to identify comprehensive sustainable
                                                                  address care gaps for people at risk for or already living
approaches to patient care the lilly ncd partnership
                                                                  with diabetes further south in the vast rural stretches
will focus initially on diabetes in targeted communities
                                                                  of the eastern cape our partner the donald woods
in india mexico and south africa with expansion to
                                                                  foundation is building on its success with homebased
brazil in late 2012
                                                                  hiv programs to include improved diabetes care

india
in india lilly has joined forces with the public health
foundation of india population services international and
project hope to implement a comprehensive program
to address low levels of diabetes awareness and uncoor
dinated healthcare services the project covers 400000
people in two locations sonipat near delhi and vizag
on the east coast and includes awareness activities
healthcare provider training and patient care




     16              lilly 20112012 corporate responsibility update

                                                enhancing access to medicines

                        01          02          03
                                                03          04            05       06          07          08         09




the lilly mdrtb partnership
recognizing that the spread of multidrugresistant                   the eli lilly and company foundation the foundation        india
tuberculosis mdrtb could not be halted by medicine                recently made a fiveyear 20122016 30 million           the partnerships training programs reach pharmacists
alone lilly launched the lilly mdrtb partnership in                commitment to support organizations in the lilly             nurses rural healthcare providers and private practitioners
2003 according to the world health organization more               mdrtb partnership this commitment marks the                in several states including andhra pradesh maharashtra
than 650000 people are currently infected with mdrtb              third and final phase it will focus on                     tamil nadu and west bengal
and far too few are being diagnosed and treated
                                                                      providing training for healthcare providers from pro
                                                                                                                                  russia
for almost 10 years the lilly mdrtb partnership                      fessional health workers such as nurses and doctors
                                                                                                                                  in russia the partnership will research the benefits of
the partnership has worked with the worlds leading                  to informal caregivers such as community volunteers
                                                                                                                                  training healthcare providers and demonstrate the positive
organizations to battle mdrtb lillys initial contributions         improving the supply of and access to safe effective     effect that wellmanaged treatment and care has on
included 120 million in cash medicine advocacy tools               and highquality mdrtb drugs at the end of 2010         the health of mdrtb patients this work will take place
and technology focused on prevention diagnosis and                  less than 16 percent of estimated mdrtb patients          in the regions of saint petersburg voronezh and the
treatment of patients with mdrtb and nearly 20 million              globally received the drugs they needed                   mari el republic
in additional funds to the lilly tb drug discovery initiative
to accelerate the discovery of new drugs to treat tb                the foundation will work with partners at the global and
                                                                     local level with a specific focus on partners in the four   south africa
weve achieved a lot                                                countries carrying the highest burden of mdrtb china      in south africa the partnership supports the national
 weve transferred manufacturing technology to seven                india russia and south africa for more information       governments plans to expand and decentralize mdrtb
  companies to increase availability of mdrtb medicines            please visit wwwlillymdrtbcom                           diagnosis and care by enhancing healthcare provider
                                                                                                                                  capacity it does so by investigating current healthcare
 weve trained more than 100000 healthcare professionals
                                                                     china                                                        training programs in a variety of settings identifying what
  to better recognize diagnose and treat mdrtb
                                                                     the partnership trains medical professionals in six          works best so it can be replicated as well as pinpointing
 weve distributed guidelines and toolkits to more than                                                                          further needs for action
                                                                     chinese provinces namely fujian hebei jiangxi
  45000 hospitals and clinics and
                                                                     liaoning sichuan and xinjiang on mdrtb prevention
 weve reached millions of people in highrisk communi             and screening
  ties through innovative public awareness campaigns




     17                 lilly 20112012 corporate responsibility update

                                               enhancing access to medicines

                       01          02          03
                                               03          04            05       06          07          08         09




improving access to drugs
that treat mdrtb
currently far too few mdrtb patients receive the                  institute of medicine iom
drugs they need its estimated that fewer than 46000              research project
people worldwide are receiving verified treatment with
                                                                    the partnership is sponsoring a global effort by the iom
drugs for mdrtb out of an estimated 650000 infected
                                                                    to assemble leading experts on mdrtb to evaluate
with mdrtb a range of issues contributes to challenges
                                                                    efforts to increase the supply of mdrtb medicines and
to drug access including poor forecasting of product need
                                                                    to vet new ideas to improve access to these medicines the
limited laboratory capacity for diagnosis underperforming
                                                                    iom will convene two meetings of current leading thinkers
markets pricing and inadequate resources to strengthen
                                                                    to help ensure mdrtb remains a global health priority
the systems needed to manage the complex treatment
regimens required by these patients the partnerships
work in this area focuses on developing new thinking that           innovation summit
can be translated to measureable action                            the partnership hosted an innovation summit in 2012 to
                                                                    bring supply chain experts together with entrepreneurial
collaborations with mdrtb advocates                                thinkers from inside and outside the healthcare field to
                                                                    look at access issues in innovative ways the summits
this initiative pulls together leading experts and stakeholders
                                                                    output includes 12 actionable ideas for addressing barriers
in the field to analyze bottlenecks to access and propose
                                                                    the best of these ideas will be pursued through collabora
solutions so that patients have access to affordable
                                                                    tions with other organizations working in the tb field
qualityassured treatment




      18               lilly 20112012 corporate responsibility update

                                         developing innovative medicines

     01          02          03          04            05        06        07   08   09




                                                                                          04

                                                                                          developing
                                                                                          innovative
                                                                                          medicines
                                                                                          for more than 136 years lilly has discovered
                                                                                          developed and acquired innovative new
                                                                                          medicines that address key unmet medical
                                                                                          needs worldwide to take a molecule from
                                                                                          discovery to clinical development to commer
                                                                                          cialization requires the perfect combination
                                                                                          of a promising molecule specialized scientific
                                                                                          expertise and sufficient funding at all stages
                                                                                          of the development and use of our medicines
                                                                                          lilly strives to maintain the highest standards
                                                                                          of ethical behavior this begins with our
                                                                                          bioethics program and guiding principles
                                                                                          and is reflected in our commitment to
                                                                                          protect the human rights and wellbeing
                                                                                          of clinical research subjects as well as the
                                                                                          welfare of animal research subjects



19   lilly 20112012 corporate responsibility update

                                                          developing innovative medicines

                      01          02          03          04            05        06         07          08         09




innovation starts here
to further support our commitment to speeding the                  lilly innovation fellowship awards
delivery of innovative new medicines to patients we have
                                                                   the lilly innovation fellowship awards foster postdoctoral
launched the innovation starts here global initiative
                                                                   career development through the selection of highly
innovation starts here fosters innovation and quality
                                                                   innovative research proposals lilly has created this
science through the institution of internal and external
                                                                   program to broaden postdoctoral scientists training
programs designed to enhance basic science harness
                                                                   experiences and better prepare them for a broad range
innovation and aid in the discovery and development of
                                                                   of careers including in the pharmaceutical industry the
innovative new medicines for patients worldwide
                                                                   awards establish a precompetitive academic industry
two key components of this initiative include the lilly            training partnership where a postdoctoral fellow and
research awards program and the lilly innovation                   academic mentor are paired with a lilly scientist to provide
fellowship awards through both lilly scientists will             the industry resources that can enable the advancement
collaborate with academic researchers on projects that will        of the postdoctoral scientists research proposal in 2012
aid in the advancement of lillys pipeline for the future         the lilly innovation fellowship awards will be by invitation
                                                                   only to applicants at academic research centers in the
lilly research awards program                                      united states and the united kingdom

the lilly research awards program brings together a
diverse group of scientists worldwide in an effort to further
the advancement of research in important therapeutic
areas where lilly has expertise including neuroscience
cancer diabetes immune system disorders and others




     20               lilly 20112012 corporate responsibility update

                                                              developing innovative medicines

                          01           02           03        04            05        06         07          08          09




biopharmaceutical rd is highly                                       lilly collaborates to help
 complex and the formation of                                         accelerate development of
                                                                       new medicines
 transcelerate biopharma inc
 underscores our belief that                                           lilly is often in the midst of a clinical study for which it   heads of research and development from the member
                                                                       needs a competitors medicine for comparison this can         companies will compose tbis board of directors including
 the only way we can address                                           be a costly and timeconsuming task but one that is           jan lundberg phd executive vice president of science
 industrywide challenges is by                                        vital to determining the molecules safety and efficacy in     and technology and president of lilly research
                                                                       relation to currently available treatmentsespecially in       laboratories members of tbi have identified clinical
 coming together and sharing                                           todays environment where regulators are demanding             study execution as the initiatives initial area of focus
 best practices with the ultimate                                     differentiation from these currently approved medicines       five projects have been selected by the group for funding
                                                                       what if the pharmaceutical industry could come together        and development member companies have agreed to
 goal of accelerating the pace                                         to develop a more timely and costeffective solution           equally share financial commitment personnel information
 at which innovative medicines                                         to getting the necessary comparator medicines into             and risk in these areas including
                                                                       clinical studies
 reach patientswhether from                                                                                                           development of a shared user interface for investigator
                                                                       a new industrywide coalition transcelerate biopharma          site portals
 lilly or others                                                     inc tbi was formed to solve this challenge and others       mutual recognition of study site qualification and training
                                                                       that arent possible for one pharmaceutical company to
                                                                                                                                       development of riskbased site monitoring approach
jan lundberg phd                                                    address on its own tbi represents a firstofitskind
                                                                                                                                        and standards
executive vice president of science and technology and                development a consortium of pharmaceutical companies
president lilly research laboratories                                 collaboratingin a precompetitive environment lilly            development of clinical data standards and
                                                                       joins nine other partners as founding members of tbi           establishment of a comparator drug supply model
                                                                       including abbott laboratories astrazeneca boehringer
                                                                       ingelheim bristolmyers squibb glaxosmithkline
                                                                       johnson  johnson pfizer roche and sanofi




       21                 lilly 20112012 corporate responsibility update

                                                          developing innovative medicines

                      01          02          03          04            05        06           07         08         09




bioethics                                                                                                                          bioethics pioneer
the lilly bioethics program is designed to address                 the lilly bioethics advisory committee and the
                                                                   lilly bioethics network
                                                                                                                                   lilly was one of the first pharmaceutical
the increasingly complex ethical challenges of global
pharmaceutical research and development rd in                   the beac is a crossfunctional volunteer committee              companies to establish a standing bio
todays fastpaced biotechnology environment the                  comprising seniorlevel employees from areas within             ethics committee 1999 and program
program promotes ethical research and drug development            and outside of rd including medical patient safety          2008 today fulltime professional
safeguards the integrity of the scientific process and            discovery research veterinary resources legal corporate
                                                                   affairs and global brand development membership also
                                                                                                                                   staff helps to promote ethical practices
protects patients rights and wellbeing
                                                                   includes two external academic bioethicists members            throughout lilly operations in 2012
promoting responsible human research                               take basic training in bioethics provide advice on bioethics   more than 17 senior leaders sat on the
                                                                   consultations and offer input into company bioethics
the purpose of the lilly bioethics program is to assist                                                                            lilly bioethics advisory committee
                                                                   projects such as the development of lillys official
employees in identifying and addressing bioethical
                                                                   position on a bioethics issue the ben is an informal
issues related to lillys rd activities the program
                                                                   voluntary virtual community of more than 100 lilly
is an independent organizational unit within lilly with
                                                                   employees who are interested in developing their
fulltime professional staff and a senior leader the
                                                                   knowledge and skills in bioethics
vice president of bioethics all committed to promoting
excellence in ethics support for the program also
comes from the lilly bioethics advisory committee                  position                                     consultations
beac and the lilly bioethics network ben                      development

the lilly bioethics program comprises four core activities
 establishing and articulating company positions on
                                                                                            bioethics
  key bioethics issues                                                                      at lilly
 consulting with lilly staff
 conducting internal education and training on
  bioethics and
                                                                   education                                    collaborations
 contributing to internal collaborative projects that inte
                                                                   and training
  grate bioethics into rd operations as well as external
  projects that contribute to the advancement of the field
  of bioethics as it relates to pharmaceutical applications




     22               lilly 20112012 corporate responsibility update

                                                          developing innovative medicines

                      01          02          03          04            05        06        07          08         09




lillys approach to bioethics                                     the pharmaceutical research and manufacturers of             informed consent
                                                                  americas principles on conduct of clinical trials in       one key aspect of protecting research participants
bioethics framework for human biomedical research                addition to the applicable laws and regulations of the       is the informedconsent process designed to respect
lillys ethical commitment beyond legal compliance                country or countries in which a study is conducted in       an individuals autonomy and protect an individuals
lilly strives to maintain the highest standards of ethical        choosing locations worldwide to conduct clinical trials     freedom of choice each patient or volunteer who wishes
behavior in all aspects of the companys business consistent     lilly considers the local prevalence of the disease          to participate in lillysponsored research is informed
with our brand in 2010 to provide researchers with guiding      under study and the medical research capabilities of         both verbally and in writing of the purpose methods and
principles and practical tools lilly developed a bioethics       the candidate institutions                                  possible risks and benefits of a study as well as the fact
framework specifically to describe and evaluate the ethics                                                                     that he or she is free to withdraw from the study at any
                                                                  in addition lilly works with local ethics committees
of developing conducting analyzing and disclosing results                                                                   time and for any reason the decision to volunteer for
                                                                  andor health authorities as appropriate to ensure
from studies involving human subjects the framework                                                                           a study must be an individual choice free from undue
                                                                  that conducting the proposed research in each location
incorporates company values ethics principles from widely                                                                     influences that might persuade a person to consent to
                                                                  is scientifically and ethically justified these decisions
recognized global guidelines and scholarly literature                                                                        greater than reasonable risk to help ensure this it is
                                                                  take into consideration
                                                                                                                               lillys policy that the promise of payments of money or
lilly bioethics program members employ the bioethics
                                                                   the risks and benefits for research participants          other rewards not be so large as to unduly influence a
framework when they conduct ethical analysis to answer
                                                                   the relevance of the research to local health needs       prospective subjects decision the individuals consent
consultation questions and develop bioethics positions
                                                                                                                               to participate in a study is documented by a signature
                                                                   the potential for the research to yield important
                                                                                                                               of agreement in the case of an individual who is not
protecting research subjects rights in clinical trials             scientific advances and
                                                                                                                               capable of giving informed consent including children
lilly places paramount importance on the safety and
                                                                   intent to register the drug in the host country           the consent of a legally authorized representative may
wellbeing of individual research participants our
                                                                                                                               be obtained on behalf of that individual provided that the
bioethics framework is the basis for a single global
                                                                                                                               study participant provides his or her assent to participate
standard that lilly applies to the conduct of clinical
trials worldwide our practices are consistent with




     23               lilly 20112012 corporate responsibility update

                                                         developing innovative medicines

                     01          02          03          04            05        06         07          08          09




summaries of lillys positions                                    use of placebo control                                          lilly global quality
                                                                  lilly believes that the use of placebo controls in the
stem cell research                                                                                                                organization
                                                                  development of new medicines can be scientifically
lilly believes in the scientific potential of stem cell
                                                                  valuable and ethically justifiable provided the use of the
research but also acknowledges that there are conflicting                                                                        lillys global quality team is an independent
                                                                  placebo meets several key conditions and the decision to
views about the ethics of using stem cells derived from
                                                                  conduct a placebocontrolled trial is made after a careful      organization within lilly comprising more
certain sources to support scientific innovation respect
                                                                  analysis of scientific and ethical considerations risks to     than 2400 individuals including scientists
human life and respect stakeholder views lilly uses
                                                                  research participants and local regulatory requirements
stem cells that are derived from animals and from                                                                                pharmacists and other technical quality
human sources where appropriate informed consent                                                                                  professionals the team is involved in the
                                                                  compassionate use of investigational medicines
andor assent can be obtained and there is little risk of
                                                                  compassionate use refers to the authorized use of               entire lifecycle of the molecules we develop
harm to the sample donor
                                                                  medicines that are still in the investigational phase of        working across all phases of drug develop
                                                                  development typically to treat serious and lifethreatening
human biological samples                                                                                                          ment the teams goal is to provide effective
                                                                  diseases lilly develops medicinespecific guidelines for
human biological samples have long been utilized in                                                                               guidance and quality oversight collaborating
                                                                  when such a request may be considered in general lilly
preclinical and clinical pharmaceutical research but they
                                                                  authorizes a compassionateuse program based on the             with colleagues in research and development
play an increasingly important role in the posthuman
                                                                  investigational medicines phase of development benefitrisk   and manufacturing to assure regulatory
genome era specifically dna samples are essential
                                                                  profile and probability and timing of regulatory approval
to understanding how genome variations affect or are                                                                              and lillys quality standards and controls
affected by pharmaceutical interventions because of              for more information about lilly bioethics visit              are followed
the individualized information that can be extracted from         wwwlillycomresponsibilitymedicinedevelopment
dna samples lilly commits to protecting and using                pagesbioethicsprogramaspx
data derived from samples in a responsible manner
that minimizes the potential for physical dignatory
discriminatory or stigmatizing harms




     24              lilly 20112012 corporate responsibility update

                                                          developing innovative medicines

                      01          02          03          04            05        06          07          08            09




lilly quality putting                                                   integrated global quality system
patients at the center
                                                                         the quality process is fully integrated into each and every stage of drug development the design phase
of everything we do                                                      the delivery phase and the monitoring phase

lilly is known for superior qualityin our clinical trials
our products and the information we provide to our
customers producing quality medicines is our chief
responsibility and it is what protects the bond of trust
between lilly and our customers every day we work to
make sound decisions consistent with current regulations
science and the best interests of patients our goal is
to always carefully listen to patients and customers and
to respond through continuous improvement

to meet the expectation of quality that is lillys hallmark
our quality team updates and manages the lilly quality
                                                                                                 design                  deliver                          monitor
system providing the foundational quality requirements                                          clinical development    safety and efficacy data         safety
for processes throughout the product development cycle
                                                                                                 product development     manufacturing and distribution   product complaints
an integrated structure of standards business processes
organizational and management controls the lilly quality                                       market research         product information              patient experience
system is designed to assure that highquality medicine and
information gets to every patient every time the system
harmonizes quality approaches as needed among internal
and external contract manufacturers of lilly medicines and
provides the overall quality direction across the company

to ensure we are able to meet these standards lillys
quality organization provides onsite support as well as
conducts an annual riskbased audit plan to oversee both
internal lilly and external partner operations audit results
provide us with the knowledge we need to continue to make
improvements to our quality controls and systems




      25              lilly 20112012 corporate responsibility update

                                                          developing innovative medicines

                      01          02          03          04            05        06          07          08          09




global manufacturing                                                                                                              diversity in clinical trials
more than 6000 individuals at 23 sites work in lillys             studies must be designed and conducted with due              minority populations have historically and consistently
global manufacturing organization this group is                     consideration for the relevance of the study to human        been underrepresented in clinical trials as a result
responsible for the companys safe production of a                   or animal health and to the advancement of knowledge       important information about how medicines work in
continuous supply of highquality medicine for patients             animals must be provided with living conditions that         minority populations is not always available this issue
worldwide global manufacturing partners with lillys                are appropriate for the species and that will contribute     is critical because patients responses to medicines can
business areas to help deliver value through a                       to their health and wellbeing                              vary by ethnicity lifestyle and genetic background
commitment to scientific excellence quality cost
                                                                    personnel who care for animals or who design or              to help boost enrollment of diverse populations in trials
effectiveness and integrity to maintain continuous
                                                                     conduct animal studies must be appropriately qualified       and make trials more accessible to minority communities
improvement manufacturing consistently invests in the
                                                                     and trained                                                 lilly has partnered with professional and advocacy
people processes and technology needed to ensure the
                                                                    animals must be treated humanely with pain                  organizations to launch awareness campaigns and set
quality people expect when they select a lilly product
                                                                     and distress eliminated or minimized                        goals across our therapeutic and product lines to achieve
                                                                                                                                  greater diversity among patients enrolling in new clinical
                                                                    animal testing will be performed after consideration
                                                                                                                                  trials since 2008 we have introduced nearly 300 new
animal care and use                                                  of the three rs replace animals whenever scientifically
                                                                                                                                  clinicaltrial sites in the united states in locations with
                                                                     valid and acceptable alternatives exit reduce the
                                                                                                                                  minority patient populations of more than 25 percent
at lilly we believe we have a moral ethical and scientific        numbers of animals used and refine procedures to
responsibility to ensure the welfare of animals used for             minimize distress                                           our outreach has included multiple presentations on the
any purpose by our company our policy and standards                                                                              need for diversity in clinical trials to such organizations
                                                                    studies involving animals must be designed
regarding the use of animals are based upon the us                                                                              as the national medical association nma the national
                                                                     and conducted in accordance with applicable
government principles for the utilization and care of                                                                             hispanic medical association nhma the american
                                                                     country and local regulatory guidance
vertebrate animals used in testing research and training                                                                        medical association ama the education network
                                                                   it is our intent that all lilly facilities are accredited by   to advance cancer clinical trials enacct the ama
to assess the potential safety toxicity and efficacy of          the association for the assessment and accreditation           commission to end health care disparities and the
compounds for human use lilly researchers must                    of laboratory animal care aaalac aaalac provides            american association for cancer research aacr we
conduct in vivo studies when other acceptable alternatives         an independent review and confirmation of appropriate          also have conducted several national regional and local
do not exist when conducting such assessments all                animal care and use in the united states lillys animal      panels reaching journalists advocates and healthcare
personnel must comply with our policy and with the                 care and use committees approve and oversee animal             providers concerning healthcare disparities and our
following principles                                              use similarly lillys ethical committee reviews animal       clinicaltrial diversity strategy
                                                                   usage in the united kingdom




      26              lilly 20112012 corporate responsibility update

                                                     developing innovative medicines

                 01          02          03          04            05        06        07   08   09




breaking barriers to
diverse clinical trials
to help address barriers to access to trials
our clinicaltrial diversity strategy includes
the following activities
 translating patient materials into spanish
 providing physician education materials
  that include background on the different
  needs of distinct patient groups
 partnering with advocacy organizations to
  raise awareness about health disparities and
  the need for diversity in clinical trials and
 actively recruiting investigators with
  diverse patient populations




   27            lilly 20112012 corporate responsibility update

                                                                                   developing innovative medicines

                                   01              02              03              04              05               06              07        08   09




                                                                                                                                                        76                       36
 lilly diversity in clinical trials in the united states10

 we need more diverse representation in clinical trials to gain insights for making medicines that are
 most effective for all people who use them lilly aims to better match the demographic composition
 of clinical test groups with the disease prevalence rate in the general population
                                                                                                                                                        sites in the west        sites in the northeast




                                                                                                                                                        37
                                                                                                                                                        sites in the midwest
                                                                                                                                                                                 95
                                                                                                                                                                                 sites in the southeast




                                                                                                                                                        26
                                                                                                                                                        sites in the southwest
                                                                                                                                                                                 5
                                                                                                                                                                                 sites in alaska and
                                                                                                                                                                                 hawaii




                                                                                                                                                        20
                                                                                                                                                        sites in puerto rico
		
     sites as of 2012
10
     a diverse clinical site is defined as any clinicaltrial site where the patient population of the medical practice not necessarily
     who they enroll into trials is more than 25 percent noncaucasian




           28                      lilly 20112012 corporate responsibility update

                                                          developing innovative medicines

                      01          02          03          04            05        06        07         08         09




tailored therapies                                                educating patients                                           lillys goal is to help improve
historically medicine has been one size fits all              when a regulatory agency approves a medicine it has
                                                                                                                                individual patient outcomes
increasingly this is changing tailored therapeutics             concluded that for the overall public the medications      because medicines dont work
promises to deliver greater precision higher value and          benefits outweigh its risks for the conditions outlined in
improved outcomes for individual patients by using a             the product label still accurate and uptodate safety
                                                                                                                                the same for everyone we need
variety of approaches to detect meaningful differences            information is critical for healthcare providers and          to understand how medicines
within patient populations and identify the right drug at        patients to best decide how and for whom a medication
the right dose for those patients                               should be used lillys role in risk management centers
                                                                                                                                work and the safety profile
tailored therapeutics is in part technical by using
                                                                  on helping healthcare providers make informed decisions       in the patients likely to take
                                                                  about how and when a medicine should be used how
emerging technologies and capabilities the pharma
                                                                  to monitor the patient for potential adverse events and
                                                                                                                                them and because culture can
ceutical industry can move toward better and more
predictable patient outcomes it is also a strategy for
                                                                  how to communicate to the patient about proper use of         strongly influence how patients
                                                                  the medication in january 2010 lilly launched a patient
enhancing the social value of medicines all medicines
                                                                  safety website wwwlillycomproductspatientsafety to
                                                                                                                                define health perception lifestyle
have potential risks and benefits tailoring allows us to
use realworld data and information and input from
                                                                  educate key external stakeholders about the role the          choices and healthcare seeking
                                                                  pharmaceutical industry the fda physicians and patients
those closest to patients to develop therapies that offer
                                                                  play in ensuring medicines are safe and effective
                                                                                                                                behaviors we need to understand
the most value to individuals and to society
                                                                                                                                relevant cultural differences that
                                                                                                                                impact patient outcomes
global patient safety
                                                                                                                               coleman obasaju md phd
lillys global patient safety organization is a team of more
                                                                                                                               senior medical director lilly oncology and
than 300 individuals including physicians pharmacists                                                                       global leader diversity in clinical research
nurses and other drugsafety professionals this group
leads the companys efforts to report adverse events
and continuously monitor the safety of lillys products
through their entire lifecycle including the identification
of changes in the benefitrisk balance




      29              lilly 20112012 corporate responsibility update

                                                       supporting strong workplace practices

     01          02          03          04            05          06         07           08   09




                                                                                                     05

                                                                                                     supporting
                                                                                                     strong
                                                                                                     workplace
                                                                                                     practices
                                                                                                     more than a century ago colonel eli lillys
                                                                                                     vision and his commitment to patients
                                                                                                     employees and communities set a strong
                                                                                                     tone for our company that continues today
                                                                                                     our business has prospered over 136
                                                                                                     years because of our peoplepeople with
                                                                                                     a talent for innovation and a passion for
                                                                                                     making a difference by finding treatments
                                                                                                     for the most stubborn diseases people
                                                                                                     whose talent is matched by their generosity
                                                                                                     and people with strong values and a
                                                                                                     determination to prevail regardless of
                                                                                                     the challenges




30   lilly 20112012 corporate responsibility update

                                                                       supporting strong workplace practices

                     01          02          03          04            05          06         07           08       09




developing our workforce
colonel lillys valuesintegrity excellence and respect         in our business effective leadership is essential so we       freedom of association
for peoplecontinue to shape our practices we strive to          have created programs and activities designed to build
                                                                                                                                  we recognize the importance of freedom of association
provide our employees an engaging and rewarding working           leadership skills our longterm responsibility is to ensure
                                                                                                                                  in the workplace and respect the right of our employees
environment built on a foundation of trust we believe we         lilly has a talent pipeline for the future just as lilly has
                                                                                                                                  to join associations of their choosing lilly interacts with
have created a workplace with fair labor practices where         to think many years in advance to plan our drug pipeline
                                                                                                                                  works councils and unions in several countries outside
employees are respected for their contributions                  we need to do the same for our people pipeline
                                                                                                                                  the united states we support these bodies and work
as a pharmaceutical company our mission is to                    effective employee collaboration is critical to lillys         productively with them the vast majority of our workers
make medicines that help people live longer healthier           success and we work to engage our employees and               globally are not covered under traditional collective
more active lives our employees are essential to us              foster and promote teamwork even in a challenging              bargaining agreements in some countries where we
accomplishing that mission the early leaders of our              business environment we believe its important to              operate governments mandate working conditions
company recognized that actions do speak louder than              invest in employee development with programs such               such as salary increases minimum wages bonuses
wordsparticularly where employees were concerned                as connecting hearts abroad this program invites 200           number of weekly working hours vacation time and
intellectual capital may be the modern term for it but         employees a year to volunteer on company time for             overtime rates these vary by country and we follow
even early on lilly management understood that the               two weeks in 10 countries where people lack access to           these mandates wherever they are required several of
knowledge and skills of lilly people were the companys           basic resources including quality health care                 our affiliates have employee councils that meet monthly
most important assets                                                                                                            with management to discuss workforcerelated issues
                                                                                                                                  that directly impact them such as company policies and
today we offer our workforce competitive compensation
                                                                       privacy concerns                                           organizational changes
and benefits packages and provide a wide variety of
opportunities for personal growth we aim to create an                 we were the first in our industry to formally
environment where employees can balance work and                       implement a policy to protect the privacy of
personal life responsibilities we provide employees with              our employees genetic information with the
opportunities to build careers that reward them personally             goal of ensuring that such information cannot
and professionally while helping our company advance
                                                                       be used to discriminate in employment and
its vision to improve patient outcomes
                                                                       benefitrelated decisions




     31              lilly 20112012 corporate responsibility update

                                                                       supporting strong workplace practices

                     01          02          03          04            05          06         07           08          09




workplace awards
were frequently ranked as one of the best companies in the world at
which to work some recent recognition includes the following




    top 50                                     top 100                                           best places to                                top 25
    companies for diversity                    best places to work
                                                                                                 work                                          global companies for leaders

    lilly ranked 29th out of 587               best places to work hall of                       corporate equality index                      lilly was ranked among the top 25
    companies that completed the               fame working mother magazine                                                                   in 2009 and 2011 by aon hewitt in
    diversityinc survey 2012                19952012                                       perfect score of 100 20062012 human       partnership with fortune and the
    this was the second time lilly                                                               rights campaign the index measures an        rbl group
    made the top 50 list                                                                        organizations efforts toward creating an
                                                                                                 equitable environment for lesbian gay
                                                                                                 bisexual and transgender lgbt employees



                                               top company                                                                                     best in class
    top                                        for working families
                                                                                                                                               employers of asian pacific

    company
                                                                                                                                               american professionals finalist
                                               lilly was cited as a model of
                                               workplace flexibility for employees
                                                                                                 workplace
    for executive women                                                                                                                        asia society 2012
                                               diversityinc 2012
    national association of female
    executives 20092012                                                                       excellence award
                                                                                                 finalist out  equal 2012




     32              lilly 20112012 corporate responsibility update

                                                                            supporting strong workplace practices

                          01             02            03     04            05          06         07           08          09




top company for
working families
in 2012 diversityinc named lilly as the top company for               globally lilly offers a number of programs varying by
working families the diversity assessment firm honors                 location to assist employees in maintaining worklife
a select group of companies each year for leadership                   flexibility these include flexible work arrangements
and innovative solutions that demonstrate the next wave                personal leaves onsite health servicesfitness centers
of diversitymanagement success in particular lilly                  as well as onsite child care credit unions dry cleaners
was honored for being a model of workplace flexibility                 and family support programs
for employees
                                                                       for lilly flexibility is about being able to recruit and retain
                                                                       the best talent in a competitive marketplace preparing for
                                                                       the changing environment and reducing costs related to
  lilly recognizes the critical importance of                         absenteeism for our employees flexible work schedules
   worklife integration tools to address the                          can lead to reduced stress better health and a stronger
   diverse needs expectations lifestyles and                        focus on work overall flexibility leads to improved levels
   work styles of employees allowing them                             of employee engagement which drives productivity
   to be the most effective

  john c lechleiter phd
  lilly chairman president and chief executive officer




     33                   lilly 20112012 corporate responsibility update

                                                                        supporting strong workplace practices

                      01          02          03          04            05          06         07           08         09




diversity and inclusion                                                                                                              us workforce 2011



                                                                                                                                                               47     
at lilly embracing diversity is at the core of our longheld      disparities and address the unique healthcare needs
value of respect for people it is the lens through which          of all communities our diversity commitment extends
we understand and respond to the unique needs of the               through the full spectrum of our business including



                                                                                                                                                                53
millions of individuals who depend on our medicines               our clinicaltrial strategy and our supply chain
were proud of our diversity and the essential role it plays
in helping us accomplish our mission making medicines
                                                                   we are working to further embed diversity within the                                           
                                                                   culture at lilly by integrating it into every aspect of our
that help people live longer healthier more active lives
                                                                   businessfrom marketing practices to how we hire our
creating and maintaining a nondiscriminatory work                  employeesand were seeing good results for example
                                                                                                                                     global workforce 2011
environment is a key priority for us at lilly our code            we have twice been named to diversityincs list of top



                                                                                                                                                               46
of business conduct which we call the red book                 50 companies for diversity which is widely recognized
requires employees to behave so that the workplace
is free of improper conduct and harassment and other
                                                                   as the premiere thirdparty diversity assessment in the
                                                                   united states in the 2012 list lilly ranked 29th out of 587
                                                                                                                                                                      
inappropriate forms of discrimination for more                  companies that completed the survey diversityinc also


                                                                                                                                                                54
on the red book see page 08 for lilly employees                cited lilly in 2012 as a model of workplace flexibility for
embracing diversity means understanding respecting               employees see page 33
and valuing differences including but not limited to
                                                                   we recently have stepped up our diversity and inclusion
race religion gender sexual orientation work style
                                                                   efforts with a more visible and businessbased commitment
national origin and age
                                                                   that focuses on people in all areas of our global organization   minority employees 19 of us workforce
lilly works to attract and retain talented employees               in our manufacturing arena for example were promoting
who bring the varying perspectives and skills we need
to operate on a global level diversity fosters creativity
                                                                   the effort under the banner what makes you unique makes
                                                                   us stronger were developing and adopting a formal              7                     3
creativity drives innovation and innovation leads to              business case for diversity and inclusion based on the
better patient outcomes and enhanced business success             notion that every person and every decision counts               asian                  latino
without diverse ideas we simply cannot remain viable
                                                                   we also have increased our leaders accountability for
in a rapidly changing environment

we partner with advocacy groups professional societies
                                                                   developing diverse talent our senior leaders have perfor
                                                                   mance objectives focusing on mentoring and careerpath            7                     2
community organizations public and private healthcare             planning for women and diverse employees globally
administrators and others to help reduce health                                                                                     african american       other




     34               lilly 20112012 corporate responsibility update

                                                                        supporting strong workplace practices

                      01          02          03          04            05          06         07           08    09




fighting for inclusion                                             health safety and wellness                                 women are an important
we are proactive in working in the legal system to ensure
                                                                   protecting the health and safety of our employees is          customer since they make the
that the communities in which we operate are open and
welcoming we are coming from the perspective of a large
                                                                   one of our foremost priorities and is consistent with         majority of healthcare decisions
                                                                   our company value of respect for people in 2008 lilly
indiana employer with a global and diverse workforce
                                                                   established goals to reduce employee injury rates by 50       for themselves and their families
many of lillys employees are scientists medical doctors         percent by the end of 2013 compared to 2007 see data        to understand and meet those
pharmacists and engineers who are critical to the                 page 37 to meet these injury reduction targets weve
research and development of new medicines we recruit              focused on situations that pose the greatest risks for        diverse needs we need to make
worldwide for these highly skilled people in an intensely          our employees worldwide slips trips and falls motor       sure everyone has the opportunity
competitive environment for excellent employees our               vehicle collisions and ergonomic risks
ability to thrive in our home state of indiana is dependent                                                                      to contribute and lead
                                                                   not only were the goals both aggressive and aspirational
on an environment that is welcoming
                                                                   they accomplished what we hoped they would a change
that is why we continue to raise our voice in opposition           in workplace behaviors and a reduction in the severity
                                                                                                                                eiry roberts md
to a proposed indiana constitutional amendment that bans           of injuries across our global operations at the end of      chair of the lilly womens network
                                                                                                                                and vice president lilly biomedicines
samesex marriages and civil unions lilly views this              2011 we had reduced the rates of serious injuries and
proposed amendment as harmful and overreaching in                 losttime injuries by 24 percent since 2007 the motor
addition to restricting marriage and civil unions it could        vehicle collision rate per million miles meanwhile
pose challenges to the extension of domestic partner               dropped by 7 percent during the same time period            we believe diversity is critical
benefits this amendment is harmful to lilly as we seek            despite solid progress were currently not on track to
to attract and retain great talent and is detrimental             meet our 2013 reductions                                     to innovation our inclusion on
to indianas efforts to be a life sciences leader which
                                                                   our injury prevention efforts have been impeded by several    the diversityinc list of the top
requires a critical mass of worldclass talent in the
private sector and at our academic institutions lilly is
                                                                   challenges for example as our health and safety programs    50 companies for diversity is a
                                                                   have matured in our facilities in emerging markets weve
prepared to continue our strong advocacy against having
                                                                   seen more consistent reporting of workrelated injuries       great honor and validation of our
this unfair language incorporated into indianas highest
legal document
                                                                   and illnesses globally this means that our serious injury    efforts to create an environment
                                                                   rates are not declining as quickly as we would like them
                                                                                                                                 where innovation can flourish

                                                                                                                                shaun hawkins
                                                                                                                                chief diversity officer




     35               lilly 20112012 corporate responsibility update

                                                                                   supporting strong workplace practices

                                01             02              03          04      05          06         07           08        09




     2013 goals11                                                               tonot because more people are getting hurt but because      early on in the formation of the wellness and productivity
                                                                                injuries are being reported with greater integrity we want   team we realized that our mission as an organization
                                                                                all of our locations to report injuries when they happen      needed to mirror what we call the lilly promise part of




     50                   
                                                                                so we can learn from the incidents and help avert similar     that promise is our commitment to making medicines that
                                                                                episodes in the future                                       help patients live longer healthier more active lives we
                                                                                                                                              need to do the same for our employees and their families
                                                                                ergonomic improvements have been a key priority for us
                                                                                                                                              in recognition that we experience the same individual
                                                                                in recent years weve been focusing on ways to adjust
                                                                                                                                              stresses issues and challenges as all others
                                                                                the job to fit the employee rather than the other way
     reduction in serious injury rate                                           around were integrating ergonomic design criteria into      when people hear the term wellness they often
                                                                                capital improvement projects within the workplace and        think about the physical aspects of health and fitness
                                                                                we routinely host training sessions for employees in all      to fulfill our promise to employees we thought it was




     50                   
                                                                                types of job categories in 2011 lilly invested millions     important to broaden this view of wellness by promoting
                                                                                of dollars in capital projects and professional services      the multiple dimensions that contribute to personal
                                                                                to implement employees ideas further improving              wellbeing physical financial social career and
                                                                                ergonomic conditions in offices laboratories sales fleet   community in 2012 we launched fit for life a set of
                                                                                and manufacturing plants                                     tools and resources to help employees not only better
     reduction in losttime injury rate                                                                                                       manage their health but also identify those things that
                                                                                in june 2011 lilly made a renewed investment in the
                                                                                                                                              can contribute to a more healthy and active life some
                                                                                wellbeing of our employees through the launch of a new
                                                                                                                                              of the fit for life offerings include the following free




     50
                                                                                global compensation and benefits program including


                          
                                                                                                                                              health screenings wellbeing assessments and plans
                                                                                the formation of a wellness and productivity team the
                                                                                                                                              health coaching and access to fitness centers
                                                                                team has direct responsibility for us wellness strategy
                                                                                worklife operations health management and promotion        in 2011 we continued to push toward reducing the rate
                                                                                and employee activities as well as leaves and disability    of motor vehicle collisions involving our sales teams
                                                                                there are similar wellness teams at several of our            who spend much of their time on the road through our
     reduction in motor vehicle collision                                       international locations                                      motor vehicle safety program thousands of lilly sales
                                                                                                                                              representatives have received behindthewheel training


11
     goals are based on a 2007 baseline the serious injury rate is
     defined by the number of workrelated injuries and illnesses that
     require medical treatment beyond immediate first aid per 100
     employees working fulltime for a year the losttime injury rate
     which reflects the severity of serious injuries equals the number
     of serious injuries that result in an employee missing at least one
     day of work per 100 employees working fulltime for a year




         36                     lilly 20112012 corporate responsibility update

                                                                       supporting strong workplace practices

                     01          02          03          04            05               06              07               08              09




on how to be better defensive drivers we emphasize                            serious injury rate12                                  losttime injury rate                                   motor vehicle collision rate
the importance of maintaining a safe operating distance
                                                                               per 100 employees                                      days or workdays per 100 employees                    collisions per million miles driven
between vehicles and of avoiding distractions such
as texting or talking on a cell phone that impede                             2007                                   144             2007                            062                   2007                                      1110
focused driving
                                                                               2008                            118                    2008                           059                    2008                                         1206
were pleased to report that we had no workrelated
employee fatalities during 2011 lilly continues to
                                                                               2009                     092                           2009                038                               2009                                      1117
emphasize prevention of catastrophic events weve                             2010                      096                          2010                 041                              2010                                   1048
recently begun identification assessment and management
of everyday workplace risks that if done incorrectly or                       2011                         109                       2011                    047                           2011                                   1028
out of sequence can result in serious injuries or death                      2013 goal           072                                2013 goal        031                                  2013 goal             550
we expect to standardize such evaluations across the
company over the next several years

we want our employees to be healthy and productive
at lilly and in their lives outside of work our robust                        serious injury accident category                                                   losttime injury accident category
management systems rigorous health and safety
programs and emphasis on employee engagement serve
as the cornerstones to success in reducing injuries                                                                                           37                                                                                  21
                                                                                                                                               sprainstrainergo risk                                                              sprainstrainerg
                                                                                         21                                                                                  17                 21
                                                                                                                                               15                                                                                  24
                                                                                                                 37                           sliptripfall                                                                       sliptripfall

                                                                                                                                               27                                                                                  38
                                                                                                                                               motor vehicle
                                                                                      27                                                      collision                  38                        24                            motor vehicle
                                                                                                                                                                                                                                    collision
                                                                                                         15                                   21                                                                                  17
                                                                                                                                               other                                                                                other


                                                                                   sprainstrainergonomic risk                   sliptripfall            motor vehicle collision               other

                                                                          12
                                                                               2013 goal 2007 baseline for all three workplacerelated metrics some health and safety data from prior years were adjusted slightly due to updated data collection




     37              lilly 20112012 corporate responsibility update

                                                            lilly around the world

     01          02          03          04            05   06          07           08   09




                                                                                               06

                                                                                               lilly around
                                                                                               the world
                                                                                               lilly has a robust history of community
                                                                                               involvement and we believe we can make an
                                                                                               impact that extends far beyond the medicines
                                                                                               we make many of our donationsincluding
                                                                                               those provided through the eli lilly and
                                                                                               company foundationfocus on improving
                                                                                               access to medicines and quality health
                                                                                               care our company donates substantial
                                                                                               amounts of products and cash every year
                                                                                               and our employees volunteer their time
                                                                                               and skills to scores of charitable causes
                                                                                               and programs our animal health division
                                                                                               elanco focuses on hunger relief and is
                                                                                               developing the technology needed to feed
                                                                                               a growing world population elanco has
                                                                                               committed to sustainably end hunger for
                                                                                               100000 families globally through a partner
                                                                                               ship with the nonprofit heifer international



38   lilly 20112012 corporate responsibility update

                                                                                                              lilly around the world

                                  01             02             03              04             05             06             07              08             09




     lilly global community giving                                                                                                    
                                                                                                                                         30
                                                                                                                                       million
                                                                                                                                                                              6500                                          800
                                                                                                                                                                              families helped                              thousand vials
                                                                                                                                    philanthropic                                                                            of insulin
                                                                                                                                    commitment



                                                                                                                                the lilly mdrtb                           elancos hunger                             life for a child
                                                                                                                                partnership                                commitment
                                                                                                                                                                                                                       subsaharan africa asia
                                                                                                                                china russia south africa india         zambia china indonesia                    south america
                                                                                                                                this publicprivate initiative works       our elanco animal health division has       we have committed to donating more
                                                                                                                                to tackle multidrugresistant tuber       committed to end hunger for 100000         than 800000 vials of insulin to the
                                                                                                                                culosis in highburden countries in       familiesor 600000 individualsglob       international diabetes federations
                                                                                                                                2011 phase iii launched with a 30        ally by 2025 through a partnership with     life for a child program between
                                                                                                                                million philanthropic commitment           heifer international at the end of 2011   2008 and 2013 as of the end of 2011
                                                                                                                                over five years from the eli lilly and     nearly 6500 families had been helped      lilly had donated nearly 350000 vials
                                                                                                                                company foundation                                                                    to help children who have no access
                                                                                                                                                                                                                       to diabetes treatment




                                                                                                                                      
                                                                                                                                         30                                      200
                                                                                                                                                                             lilly ambassadors
                                                                                                                                                                                                                           
                                                                                                                                                                                                                              850
                                                                                                                                     million over                                                                            thousand
                                                                                                                                      five years                                                                            contributed



     charitable contributions                  disaster relief                       global day of service                      the lilly ncd partnership                  connecting hearts abroad                    global giving projects
     worldwide                                 we gave approximately 25            our annual global day of service           brazil india mexico                     asia africa central and                   guatemala haiti thailand
     in 2011 we gave more than 590           million in donations in 2011          is among the largest singleday            south africa                               south america                               turkey zambia
     million in charitable contributions       following natural disasters          volunteer initiatives of any us
     including cash products and other                                            company in 2011 we logged more           the lilly ncd partnership launched        our signature connecting hearts             the eli lilly and company foundation
     inkind donations to organizations                                             than 98000 volunteer hours in             in 2011 provides 30 million over         abroad program sends 200 lilly             and nearly 14000 lilly employees
     around the world                                                               40plus countries in indianapolis        five years to fight the rising burden of   ambassadors each year on twoweek          contributed more than 850000 in
                                                                                     we planted more than 3000 trees           noncommunicable diseases ncds           assignments to provide assistance in        support of more than 800 global giving
                                                                                     and applied 500 gallons of paint          in developing nations                     developing communities                     projects in countries around the world




		
     the programs captured on these pages represent some of our biggest philanthropic initiatives details of other community efforts can be found in our 2010 cr report




            39                    lilly 20112012 corporate responsibility update

                                                                                            lilly around the world

                          01           02         03            04             05           06          07            08            09




community giving in the united states





  25 million                                          240000                                                2000                                                  20000
educationfocused grant                                additional meals                                       teachers supported                                     pounds of watermelon
to improve public education                            served in 2011                                         financially and strategically                          grown and harvested
mind trust grant                                       childhood hunger initiative                            stem program                                           golden harvest
indianapolis                                           indianapolis                                           indiana                                                augusta georgia
our largestever educationfocused grant 25         elanco actively engages and supports the               lilly is financially and strategically supporting      elanco employees grew and harvested more than
million to the mind trust is helping improve          indianapolis childhood hunger initiative with         the implementation of the indiana science initiative   20000 pounds of watermelon and 6000 pounds
public education for underserved children in           elancos help 240000 additional meals were           in our home state supporting 2000 teachers           of pumpkins on land owned and managed by elanco
indianapolis through programs such as teach for        served in 2011                                        serving 40000 students in 2011 the lilly            augusta to benefit golden harvest a local food bank
america and a novel charter school incubator                                                                 science coaches programa volunteer program
                                                                                                              reinforcing inquirybased learningtrained 120
                                                                                                              lilly scientists and matched them to 120 teachers
                                                                                                              in marion county




      40                  lilly 20112012 corporate responsibility update

                                                                 engaging with patients

     01          02           03           04          05   06   07           08          09




                                                                                               07

                                                                                               engaging with
                                                                                               patients
                                                                                               we understand the health challenges that
                                                                                               patients and their families face and we
                                                                                               provide hundreds of millions of dollars
                                                                                               in product donations each year to help
                                                                                               but product contributions tell only part
                                                                                               of the story here at lilly we work to go
                                                                                               beyond medicine to help patients improve
                                                                                               their health and manage their diseases
                                                                                               we believe an informed patient is a better
                                                                                               participant in his or her own care and can
                                                                                               achieve better health outcomes than a
                                                                                               patient with access to less information


41   lilly 2011 corporate responsibility




41   lilly 20112012 corporate responsibility update

                                                                                            engaging with patients

                     01          02          03          04            05       06          07           08          09




supporting patients
we support and partner with numerous local and                    oncology on canvas                                             type 1 diabetes
national organizations including those addressing
                                                                  the lilly oncology on canvas expressions of a cancer          collaboration with disney
multicultural health disparities to improve patient
                                                                  journey art competition and exhibition honors the              a childs diagnosis of type 1 diabetes t1 can be over
care in the united states for example minority groups
                                                                  journeys people face when confronted with a cancer             whelming and caregivers often question if they will ever
often suffer heightened rates of certain diseases
                                                                  diagnosis the biennial competition invites individuals        be able to get their families back into any kind of daily
including diabetes which is one area of therapeutic
                                                                  diagnosed with any type of canceras well as their families   routine both parents and the child may feel the diagnosis
focus for us our preventionrelated interventions
                                                                  friends caregivers and healthcare providersto               is the end of their future hopes and dreams this customer
include materials printed in multiple languages for
                                                                  express through art and narrative the lifeaffirming         understanding served as the foundation for the lilly
traditionally underserved communities
                                                                  changes that give their cancer journeys meaning               diabetes business unit to partner with one of the most
not everyone who needs our medicines is able                      the result is a compelling art collection that provides        powerful brands in the world disney launched in 2011
to get them in the united states lilly truassist                insights into the wide range of emotions experienced           the collaboration offers healthcare providers and families
wwwlillytruassistcom provides access to products              by those touched by cancer                                    a variety of fun and informative books for children and
for eligible patients through several patientassistance                                                                         tweens including coco the first disney character
programs the majority of our product donations are               face diabetes campaign                                     with t1 lilly and disney also offer dynamic content that
made through truassist which serves as the umbrella                                                                             provides support and practical everyday tips for families
                                                                  the fearless african americans connected and
program for lillys many patientassistance efforts our                                                                         with t1 response from customers to date has been
                                                                  empowered face diabetes campaign is a grassroots
programs typically focus on our core areas of expertise                                                                         overwhelmingly positive and the collaboration will be
                                                                  movement to help african americans overcome key
including cancer diabetes and mental illness we support                                                                       expanded to multiple international markets
                                                                  barriers to success in living with type 2 diabetes african
many initiatives including the following examples
                                                                  americans are disproportionately affected by the disease
                                                                  according to the american diabetes association african
                                                                  americans in the united states are 18 times more likely to
                                                                  have diabetes than nonhispanic whites about onequarter
                                                                  of african americans between the ages of 65 and 74 have
                                                                  the disease supported by lilly the face diabetes
                                                                  campaign offers programs and tools to help people make
                                                                  lifestyle changes to manage their disease




     42              lilly 20112012 corporate responsibility update

                                                                                           engaging with patients

                     01          02          03          04            05       06         07           08          09




diabetes conversations                                            reintegration awards and scholarships
created by healthy interactions in collaboration with             founded in 1997 the lilly reintegration scholarship
the international diabetes federation lilly diabetes             is a program that helps persons with bipolar disorder
sponsors the diabetes conversations program featuring            schizophrenia and related schizophreniaspectrum
conversation map education tools this innovative                disorders by providing funding for tuition lab fees and
education method uses a unique visual approach to                books so they may pursue and achieve their educational
facilitate interactive group participation and empower            and vocational goals an independent judging panel
people with diabetes to become actively involved in               comprised of psychiatric care professionals reviews the
managing the disease the education tools available              applications and chooses the qualifying scholars
in 35 languages have been launched in more than 110
countries since 2008                                             lilly for better health
                                                                  lilly for better health is a patientfocused resource
camp care package                                                 available to community and health advocacy organizations
for more than a decade lilly has been one of the                 public and private healthcare providers policymakers and
largest providers of insulin and glucagon educational            others interested in improving the health and wellbeing
materials volunteers scholarships and special guests           of their communities lilly for better health includes a
to diabetes camps through the comprehensive lilly camp            website conference exhibits and printed materials
care package in 2011 104 diabetes camps participated            and reaches tens of thousands of customers directly each
in the camps in color program an arttherapybased               year at community events programs and healthcare
initiative for children requesting camps received 24           conferences offering valuable education materials and
million in insulin product and more than 19000 educational       interactive assessment tools on a variety of health topics
bookpacks lilly also provides camp tuition support through       in 2010 we distributed more than 450000 patienteducation
its partnership with the american diabetes association           resources to individuals and organizations

                                                                  the website which was updated in 2011 spotlights
                                                                  lilly partnerships and programs that focus on wellness
                                                                  prevention and disease management and offers ondemand
                                                                  access to health education materials many lilly for
                                                                  better health resources are available in both english
                                                                  and spanish with select tools in mandarin




     43              lilly 20112012 corporate responsibility update

                                                                      fostering environmental sustainability

     01          02          03          04            05   06   07   08          09




                                                                                                        08

                                                                                                        fostering
                                                                                                        environmental
                                                                                                        sustainability
                                                                                                        the medicines we make require the use
                                                                                                        of valuable resources including energy
                                                                                                        water and raw materials how we operate
                                                                                                        our business today can have a longlasting
                                                                                                        impact so lilly takes a broad approach
                                                                                                        to understanding and managing our envi
                                                                                                        ronmental impacts across the product life
                                                                                                        cycle we are committed to conducting
                                                                                                        our business in a patientcentered and an
                                                                                                        environmentally socially and financially
                                                                                                        responsible manner




44   lilly 20112012 corporate responsibility update

                                                                                                               fostering environmental sustainability

                     01          02          03          04            05   06                07               08               09




                                                                                      
                                                                                             18                                                                       
                                                                                                                                                                             32
our commitment and approach
our performance in meeting our environmental
goals demonstrates our commitment to reduce our
                                                                                                                    million                                                                     million
environmental footprint we believe that implementing
innovative costeffective more sustainable solutions
                                                                                      return realized by lilly during 2011 for                                        approximate cumulative reduction in
is a powerful and ongoing source of business value
                                                                                      all projects implemented so far through                                         energy spending from 20082011 helping
this section covers the broad range of our environmental                              the energy waste and natural resource                                         lilly to avoid nearly 240000 metric tons of
activities from our approach and management systems                                 reduction fund                                                                  co2e emissions
to our work addressing environmental issues across
our business to performance data and examples
illustrating progress




                                                                                      143                                million liters

                                                                                      amount of water saved per year at our
                                                                                                                                                                      10
                                                                                                                                                                      number of sites globally that reported zero
                                                                                      speke united kingdom manufacturing                                            landfill status in 201113
                                                                                      facility following enhancements to antibiotic
                                                                                      production processes




                                                                                 13
                                                                                      a site may achieve zero landfill status if less than 05 of its generated waste is sent to landfill




     45              lilly 20112012 corporate responsibility update

                                                                                                              fostering environmental sustainability

                       01           02            03           04          05          06          07         08          09




a life cycle approach

each stage of the pharmaceutical product life
cycle includes distinct environmental health
and safety impacts and offers opportunities
                                                       research and development                         materials and natural resources                   manufacturing
for improvement this graphic provides an
                                                       we consider environmental factors from           lilly customers and governments worldwide       measuring reporting and reducing lillys
overview of our work to reduce the potential
                                                       the earliest stages of design and development   are increasingly focused on the materials and     environmental impacts from manufacturing
impacts from our operations                           our design for environment initiatives include   chemicals used to make products we work          are central to the companys environmental
                                                       green chemistry environmental productrisk      to consume less materials water and other       sustainability program our manufacturing
                                                       assessments and an environmental devel         natural resources when possible                  health safety and environment hse com
                                                       opment review process to evaluate potential                                                        mittee oversees compliance with applicable
                                                       environmental issues and opportunities                                                             hse regulations policies procedures and
                                                       during the scaleup of medicine production                                                         standards while making certain that we
                                                       to manufacturing levels see page 49 for                                                           drive continuous improvement throughout
                                                       more information                                                                                  the manufacturing organization see page 51
                                                                                                                                                          for more information




sales and marketing                                    product transport and packaging                  product use                                       product endoflife
lilly continually works to improve the fuel            lillys packaging guidelineswhich cover         lilly is committed to understanding the           medicines are intended to be used in their
efficiency of our sales force vehicles to meet        areas such as reducing materials use using      potential effects of pharmaceutical products      entirety by patients and unused medicines
our internal target to reduce overall fleet            lowerimpact materials and enhancing            in the environment as well as in humans          cannot be recycled as a result models of
fuel use 10 percent globally by 2013 at lilly         packaging recyclabilityhelp us incorporate      we support using sciencebased evaluations        take back reuse and recycling in other sectors
sales and marketing offices worldwide weve           sustainability considerations into packaging     to assess and reduce the environmental risks      designed to capture value from products after
established projects to reduce energy use              decisions we track the greenhouse gas           of our pharmaceutical products through           use should not be applied to our industry we
while increasing employee environmental                ghg emissions of our product transportation    collaborations with industry partners academic   are working with customers and partners to
awareness and action                                  and distribution vendors and work with them     researchers and regulatory agencies we          ensure costeffective approaches are available
                                                       to reduce those impacts see page 50 for         continually work to further understand and        for product endoflife disposal that balance
                                                       more information                                proactively address any potential impacts         environmental risk patient privacy legal
                                                                                                        from the production distribution use and       compliance and security see page 50 for
                                                                                                        disposal of our products see page 50 for         more information
                                                                                                        more information




      46                lilly 20112012 corporate responsibility update

                                                                                                     fostering environmental sustainability

                    01          02          03          04            05       06         07         08          09




how we manage environmental issues                               hse governance                                                  audits
                                                                 lillys formal hse governance structure ensures that            each year we audit a significant portion of our sites
policies and standards                                           hse issues management is integrated companywide               globally to assess performance following the protocols
several policies and standards define our commitments            our global hse committeewhich includes senior                  outlined for each of our hse standards we use a riskbased
and guide our efforts in this area                              executives from key areas of the businessensures               approach to determine sites to audit and then reassess
                                                                 proper oversight and plays a central role in monitoring         those sites every one to five years we include external as
 our global policy on health safety and the
                                                                 corporate performance and ensuring continuous                   well as internal auditors on each audit conducted
  environment sets environmental expectations related
                                                                 improvement the global hse lead team works closely
  to compliance and environmental protection for our
                                                                 with the global hse committee to set appropriate                lillys environmental goals
  people and operations
                                                                 metrics and goals assess company performance and              setting driving toward and communicating our progress
 our environmental standard provides more detailed              oversee compliance with all hse regulations policies          toward hse performance goals is central to our hse
  requirements and establishes the core governance               procedures and standards globally the manufacturing           management approach
  requirements to manage significant environmental               hse committee supports these efforts and drives
  and energyrelated aspects of our operations                                                                                  in 2008 lilly established six hse performance goals
                                                                 ongoing improvement throughout the manufacturing
                                                                                                                                 to minimize our impact on the environment see page
 our management system standard and verification                organization executives and lead teams in each of our
                                                                                                                                 48 and reduce employee and contractor injuries these
  and corrective action standard define requirements to          business groups as well as lilly research laboratories
                                                                                                                                 goals follow from an earlier set we achieved ahead of
  ensure compliance with lilly hse standards applicable         and lilly corporate center manage governance for
                                                                                                                                 the target date demonstrating our drive for continuous
  regulatory requirements and other external hse                hse in those areas
                                                                                                                                 improvement see page 37 for progress toward our
  standards to which the corporation subscribes
                                                                                                                                 health and safety goals
 our global engineering standards govern many                   management systems
  environmental aspects of our operations such as               all lilly business units have an hse management system
  energy use and ghg emissions                                  aligned with our management system standard which is
                                                                 consistent with thirdparty standards such as iso 14001
 our product stewardship standard provides a
                                                                 ohsas 18001 and the american chemical councils
  systematic way to manage product and process risks
                                                                 responsible care management system rcms our
  in our supply chain and our operations and during
                                                                 global hse management system is also certified to
  the use of our products
                                                                 rcms several lilly facilities have obtained certification
                                                                 to these and other external standards




     47             lilly 20112012 corporate responsibility update

                                                                                                                                               fostering environmental sustainability

                                01             02              03              04              05             06              07               08              09



2013 goals 2007 baseline




              15                     
                                                                                                          15                     
                                                                                                                                                                          energy waste and natural resource
                                                                                                                                                                          reduction fund
                                                                                                                                                                          making capital investments in technology and physical
                                                                                                                                                                          plant operations can have a substantial positive envi
                                                                                                                                                                          ronmental impact however these projects compete for
              reduction in energy intensity14                                                             reduction in greenhouse
                                                                                                          gas emissions intensity1415                                    funding with other essential projects at each facility to
              progress through 201116                                                                                                                                     address this challenge we established an energy waste
              17 reduction                                                                               progress through 201116                                         and natural resource reduction fund the fund helps
                                                                                                          16 reduction                                                   pay for capital projects at our facilities globally and
                                                                                                                                                                          promotes the development of environmentally superior
                                                                                                                                                                          efficient technologies and bestpractice sharing across
                                                                                                                                                                          our facilities




              25                                                                                          40
                                                                                                                                                                          the amount spent decreased substantially in 2011 see


                                                                                                                                                                        table due to more readily available capital at the site
                                                                                                                                                                          level and shortage of the needed human resources to
                                                                                                                                                                          implement projects however the fund is ontarget to
                                                                                                                                                                          invest more than 2 million in 2012 during 2011 lilly
                                                                                                                                                                          realized a return of about 18 million for all projects
              reduction in water intake17                                                                 reduction in waste to landfill1718
                                                                                                                                                                          implemented so far
              achieved in 2009 four years early                                                          achieved in 2009 four years early
                                                                                                                                                                          energy waste and natural resource
              progress through 201116                                                                     progress through 201116                                         reduction fund expenditures
              32 reduction                                                                               66 reduction
                                                                                                                                                                           millions
              updated goal 2010 baseline                                                                updated goal 2010 baseline
              reduce water intake by 5 by 2013                                                           reduce waste to landfill by 20 by 2013                                                                               65

                                                                                                                                                                                                                         57
14
     per square foot of facility space
15
     this goal covers lillys scope 1 and scope 2 emissions                                                                                                                                                41
16
     following world resources institute guidance progress toward environmental goals is reported on an adjusted basis accounting for mergers acquisitions
     and divestitures as appropriate to ensure comparability unless stated otherwise                                                                                           08
17
     in absolute terms
18
     lillys former and current wastetolandfill goals do not include construction and demolition debris biosolids from wastewater treatment plants incinerator
     ash coal ash if reused for mine reclamation or road base and mycelia and urea reused for fertilizer




         48                      lilly 20112012 corporate responsibility update

                                                                                                        fostering environmental sustainability

                      01          02          03          04            05       06         07          08          09




product stewardship
lilly takes a broad approach to understanding and                  lillys approach to green chemistry is twofold we seek
managing our hse impacts across the product life                   ongoing improvements by reducing the amount of
                                                                                                                                       scope of health safety and environment data
cycle see page 46 our product stewardship standard              hazardous material used to make products increasing
                                                                                                                                       in this section
sets expectations for how we address sustainability                materials efficiency evaluating chemical alternatives
at each stage                                                     and avoiding the riskiest substances we also pursue                 the data in this section cover lillys global
                                                                   more fundamental changesthat can yield orderof                     operations including whollyowned subsidiaries
we focus on the following areas
                                                                   magnitude improvementsby advancing the state of the                  unless stated otherwise
 using green chemistry and design for the environment to          art in chemistry and developing and implementing new
  reduce hazardous materials use in product development                                                                                 following world resources institute guidance
                                                                   reactor technologies
  and manufacturing                                                                                                                     performance data and progress toward envi
                                                                   we have developed several continuous processes that                   ronmental goals are reported on an adjusted
 decreasing the environmental impact of product                                                                                         basis accounting for mergers acquisitions
                                                                   improve environmental performance and enhance
  manufacturing see performance in operations on                                                                                        and divestitures as appropriate to ensure
                                                                   process safety by reducing the operational scale of the
  page 51                                                                                                                              comparability unless stated otherwise
                                                                   most hazardous manufacturing steps more than one
 reducing the environmental impact of packaging                  hundredfold for example lilly scientists recently                  years are calendar years unless stated otherwise
 using sciencebased environmental risk assessments               published an article in green chemistry journal see
  to evaluate the potential impact of our products in the          detail demonstrating a new type of grignard reaction
  environment and                                                 related to edivoxetine hydrochloride production the
                                                                   innovation reduces process mass intensity by more
 disposing of products responsibly at endoflife
                                                                   than 30 percent and decreases the amount of magnesium
                                                                   and diisobutylaluminium hydride required by more
innovations in green chemistry                                     than 99 percent
in the early 1990s lilly was one of the first pharmaceutical
                                                                   lilly has also been a key contributor to the pharmaceutical
companies to use green chemistry to transform our
                                                                   roundtable and cochairs its work group on green
manufacturing processes to be safer more efficient and
                                                                   chemistry one focus area in 2012 has been developing
more environmentally friendly
                                                                   a 100000 research grant to produce safer solvents we
                                                                   have also contributed to the creation and public release of
                                                                   a harmonized solvent selection guide by the organization
                                                                   that capitalizes on several companies best practices




      49              lilly 20112012 corporate responsibility update

                                                                                                                                         fostering environmental sustainability

                               01             02             03             04             05             06             07              08          09




packaging                                                                              pharmaceuticals in the environment                                           product endoflife
pharmaceutical packaging is highly regulated and                                       lilly is committed to understanding the potential effects                    when patients dont finish their medication they should
must serve many functions including protecting product                                of pharmaceutical residues in the environment using                         safely dispose of it reuse or recycling of unused medicines
integrity during transit and storage providing information                           improved testing technologies scientists at locations                       is not a safe option for patients to help address this issue
resisting counterfeiting and protecting contents from                                 around the world have detected trace amounts of certain                      we support nationally sanctioned disposal guidelines for
tampering or access by children through our sustainable                               pharmaceutical products in streams and rivers reported                      unused medicines in the united states we also promote
packaging efforts we continually review packaging                                     concentrations are extremely low ranging from a few                         public education about proper drug disposal for example
technologies and practices to reduce the amount of                                     parts per trillion to a few parts per billion the world                     lilly is a supporter of the smarxt disposal consumer
packaging used to utilize lowerimpact materials and to                              health organization who evaluated selected investigations                  education program sponsored by the us fish and
reuse or recycle packaging throughout the supply chain                                conducted in australia the united kingdom and the united                   wildlife service the american pharmacists association
during recent years weve saved thousands of metric                                   states in those cases who found that pharmaceuticals                       and the pharmaceutical research and manufacturers of
tons of packaging and millions of dollars through these                                are present in drinking water at concentrations generally                    america phrma see lillys position on the disposal of
efforts were also collaborating with our distributors                               less than 1000 times the minimum therapeutic doses                          unused medicines in the united states
retail pharmacies and healthcare providers to better                                  and well below acceptable daily intake and drinking water
                                                                                                                                                                    we also support the proper disposal of syringes needles
understand the overall pharmaceutical packaging                                        equivalent levels according to who these levels suggest
                                                                                                                                                                    and other sharps used in home settings to mitigate
footprint and ways to reduce it                                                       that significant adverse human health impacts are highly
                                                                                                                                                                    potential public health and environmental risks based
                                                                                       unlikely through exposure to drinking water19 testing
                                                                                                                                                                    on feedback from patients and healthcare providers
packaging innovation in fegersheim france                                             continues on the impact of persistent ecotoxicity on
                                                                                                                                                                    we believe that education offers the greatest opportunity
at lillys manufacturing site in fegersheim france we                                aquatic life and the optimal path forward to address this
                                                                                                                                                                    to improve sharps disposal practices we are working
replaced disposable cardboard packaging and wood                                       issue is a subject of ongoing debate
                                                                                                                                                                    to more effectively communicate this information to
pallets with reusable plastic packaging and pallets this
                                                                                       to meet regulatory requirements and internal lilly                           patients through product user manuals patient education
decreased related waste by 6 percent equivalent to about
                                                                                       standards we assess our medicines for potential                             programs improved sales force awareness and
80 metric tons yearly
                                                                                       environmental effects before launching new products                         updated information at the lilly answer center learn
                                                                                       we regularly update our testing protocols for new and                        more at wwwlillycom
                                                                                       existing pharmaceuticals as knowledge and testing
                                                                                       methods improve we will continue to collaborate with
                                                                                       regulatory academic and research organizations to
                                                                                       advance knowledge in this area see lillys position on
                                                                                       pharmaceuticals in the environment


 19
      world health organization 2012 pharmaceuticals in drinkingwater isbn 978 92 4 150208 5 available on the who web site wwwwhoint




          50                   lilly 20112012 corporate responsibility update

                                                                                                       fostering environmental sustainability

                    01          02          03          04            05        06         07          08          09




performance in operations                                                                                                                            progress toward goalenergy use

we are committed to continually improving environmental          energy use and greenhouse
                                                                                                                                                     14000000                                      700
performance across lillys operations this includes our         gas emissions




                                                                                                                                                                                                             thousand btussquare foot
most significant areas of environmental impactenergy                                                                                                12000000                                      600
                                                                 reducing energy use and ghg emissions improves our
use and ghg emissions water use and waste we are
                                                                 environmental performance and decreases one of the                                  10000000                                      500
also committed to making further progress in green




                                                                                                                                      million btus
                                                                                                                                                                                              2013
                                                                 most substantial operational costs for our research                                 8000000                               goal
                                                                                                                                                                                                     400
procurement reducing nonghg air emissions supporting
                                                                 manufacturing and distribution activities
biodiversity efforts in communities where we operate                                                                                                 6000000                                      300
and maintaining compliance with applicable legal                 since 2006 we have conducted 29 energy assessments
                                                                                                                                                      4000000                                      200
standards as a fundamental part of our approach we             at our energyintensive sites and uncovered an estimated
establish work toward and share progress against               228 million in potential annual savings these findings                            2000000                                      100
hse performance goals see page 47                             have contributed to the approximately 32 million                                            0                                      0
                                                                 cumulative reduction in energy spending from 20082011                                           2007 2008 2009 2010 2011
see more information on our commitment to
                                                                 while helping us to avoid nearly 240000 metric tons
environmental sustainability                                                                                                                          direct energy     indirect energy      energy intensity
                                                                 carbon dioxide equivalent co2e of ghg emissions during                              consumption       consumption
                                                                 that same time period

   lilly and climate change                                      at several facilities we use renewable energy to diversify
                                                                 our energy sources and decrease ghg emissions
   climate change is an issue that is compelling
                                                                 cogeneration which involves using an onsite engine to
   governments companies and citizens to act
                                                                 generate electricity as well as recovering usable heat is
   however we do not believe it poses significant
                                                                 another important part of our approach it is currently in
   risks or opportunities for our business current
   and anticipated regulatory requirements will                  use at two sites worldwide with another one planned
   have some financial implications for lilly but
   we account for these in our routine business
   planning and we do not anticipate they will
   impact our business strategy




     51             lilly 20112012 corporate responsibility update

                                                                                                                                                   fostering environmental sustainability

                                     01              02             03              04             05              06             07               08             09




       in 2011 lillys energy use totaled 10800000 million                                 meets the required conditions these efforts enabled                                                     progress toward goalghg emissions
       btus 4 percent less than 2010 see graph on page 51                                 the site to reduce electricity use by 3 percent and gas
       since 2007 our energy intensity per square foot of facility                           use by 17 percent in 2011 compared with 2010 and save




                                                                                                                                                                                                                                                                   metric tons co2e1000 square feet
       space has improved by 17 percent keeping us on track                                  nearly 220000 per year the facility also decreased                                                    2000000                                            90
       to meet the companys goal of a 15 percent improvement                                 co2e emissions during the year by 810 metric tons                                                       1750000                                            80
       by 201320 the decrease in energy consumed between                                                                                                                                              1500000                                            70
                                                                                                                                                                                                                                                    2013
                                                                                              water use




                                                                                                                                                                                    metric tons co2e
       2007 and 2011 is equivalent to the energy used annually                                                                                                                                                                                      goal    60
                                                                                                                                                                                                       1250000
       by approximately 24000 average us homes                                                                                                                                                                                                          50
                                                                                              water is becoming a more important issue for lilly due                                                  1000000
                                                                                              to trends in availability quality and cost we consume                                                                                                      40
       during 2011 the companys scope 1 and scope 2 ghg                                                                                                                                                   750000
       emissions equaled 1530000 metric tons co2e 4 percent                                water primarily in manufacturing and production in our                                                                                                       30
                                                                                                                                                                                                            500000                                         20
       less than in 2010 see graph at right due primarily to                               parenteral operations we require exceptionally highquality
                                                                                              water to produce injectable medicines we also use                                                            250000                                         10
       reduced energy usage lillys ghg emissions intensity
       improved by 16 percent compared with 2007 keeping                                     substantial amounts of water to support our utilities                                                              0                                         0
                                                                                                                                                                                                                      2007 2008 2009 2010 2011
       us on track to meet the companys goal of a 15 percent                                 some sites have updated to waterless cooling systems
       improvement by 201321                                                                 and others have installed technology that reclaims water                                                      scope 1         scope 2               greenhouse gas
                                                                                              for this purpose to a lesser extent we also consume                                                                                               emissions intensity
       lilly also calculates scope 3 ghg emissions as included
                                                                                              water for domestic uses in our offices such as cafeterias
       in the summary data table on page 56 and not included
                                                                                              bathrooms and landscaping
       in the graph at right                                                                                                                                                                         progress toward goalwater intake
                                                                                              in 2011 we used the world business council for
       see lillys recent carbon disclosure project submission
                                                                                              sustainable developments global water tool and the
       for additional detail about the companys approach
                                                                                              united nations environment programmes vital water                                                       20
       and performance
                                                                                              graphics tool to refine our evaluation of waterstressed                                                 18
                                                                                              areas where we operate although we determined possible                                                  16
       optimizing hvac use in alcobendas spain                                                                                                                                                        14




                                                                                                                                                                                    billion liters
                                                                                              impacts to be minimal we require each of our facilities to
       use of heating ventilation and air conditioning hvac                                                                                                                                        12
                                                                                              have a local businesscontinuity plan that is generated from
       equipment represents about 75 percent of energy use                                                                                                                                             10
                                                                                              a risk assessment of all sources of business interruption
       at our alcobendas spain facility to save resources in                                                                                                                                         8
                                                                                              including water availability
       2011 the site optimized system settings and enabled                                                                                                                                              6
       equipment to enter lowenergy modes when fresh air                                                                                                                                               4
                                                                                                                                                                                                        2
                                                                                                                                                                                                        0
20		
       following world resources institute guidance progress toward environmental goals is reported on an adjusted basis accounting for mergers acquisitions and divestitures                              2007 2008 2009 2010 2011 2013
       as appropriate to ensure comparability unless stated otherwise                                                                                                                                                                goal
21		
       this goal covers lillys scope 1 and scope 2 emissions                                                                                                                                                                        updated




               52                    lilly 20112012 corporate responsibility update

                                                                                                                                                   fostering environmental sustainability

                                     01             02              03              04             05              06              07              08              09




       our manufacturing and administration groups as well as                                  in 2011 total waste generation increased 6 percent                                                      progress toward goalwaste generation
       lilly research laboratories have implemented plans to                                   from 2010 to 242000 metric tons see graph at right
       reduce water consumption and measure progress against                                   this was largely due to increased insulin production
       targets that contribute to our overall water use reduction                              at the indianapolis and puerto rico plants during the                                                     450000                                      25




                                                                                                                                                                                                                                                             metric tonsmillion  revenue
       goal we assist our sites in identifying watersaving                                   year lilly sent 10900 metric tons of waste to landfill                                                  400000
       technologies and financing                                                             down from 15900 metric tons in 2010 and 66 percent                                                        350000                                      20
                                                                                               less than 2007 see graph at right                                                                       300000
       in 2011 lillys water intake22 was 133 billion liters a 4                                                                                                                                                                                    15




                                                                                                                                                                                          metric tons
                                                                                                                                                                                                          250000
       percent increase from 2010 see graph on page 52 this                                 the reduction in total waste generated between 2007 and
                                                                                                                                                                                                          200000
       was primarily due to increased production our water                                    2011 is equivalent to the amount of waste produced in a                                                                                                 10
       intensity per unit of revenue improved by 1 percent                                     year by 27000 us residents                                                                             150000
       during that period                                                                                                                                                                                100000                                      5
                                                                                                                                                                                                           50000
       the decrease in water intake from 2007 through 2009 is                                                                                                                                                   0                                      0
                                                                                                    sales and marketing                                                                                                2007 2008 2009 2010 2011
       equivalent to the water consumed in a year by a city of
       approximately 80000 people                                                                 we recently implemented a green quest scorecard
                                                                                                                                                                                                         hazardous               nonhazardous              waste generation
                                                                                                    at our sales and marketing sites in the americas                                                    waste generation        waste generation           intensity
       waste                                                                                        canada and europe to identify and score progress
                                                                                                    toward reducing energy use water consumption
       lilly uses the following hierarchy for waste treatment                                      and transportation each year affiliates will look
                                                                                                                                                                                                        progress toward goalwaste to landfill
        eliminate or reduce the amount of waste produced                                          for opportunities to enhance their environmental
                                                                                                    performance by identifying and planning new
        reuse materials when possible often multiple times                                      projects and setting targets
                                                                                                                                                                                                        35000
        recycle used materials to make new products
                                                                                                                                                                                                        30000
        recover energy from waste
                                                                                                                                                                                                        25000
        treat waste to reduce toxicity and volume and




                                                                                                                                                                                  metric tons
                                                                                                                                                                                                        20000
        send waste to landfill only when the options above are
         not feasible                                                                                                                                                                                  15000
                                                                                                                                                                                                        10000
                                                                                                                                                                                                         5000
22		
       water intake is the total amount of water coming into a facility including water pumped from bodies of surface water and groundwater and water provided by a                                     0
       utility it includes water used in processes utilities and other ancillary operations such as irrigation the term does not include groundwater pumped solely for                                         2007 2008 2009 2010 2011 2013
       treatment to satisfy regulatory actions or requirements eg remediation activities where the water is not used for another purpose values do not include the water                                                               goal
       extracted from wells solely for the purpose of lowering the groundwater tables to maintain the physical and structural integrity of building foundations water intake                                                            updated
       values for 2010 were adjusted from previously reported values due to metering data evaluations at one of our top water use sites




              53                     lilly 20112012 corporate responsibility update

                                                                                                        fostering environmental sustainability

                     01          02          03          04            05       06          07          08          09




driving process innovation in speke                              examples include the following
united kingdom                                                     guayama puerto rico our facility maintains about
at our speke united kingdom manufacturing facility               10 acres within its grounds as an ecological habitat
antibiotic production processes require substantial                 conservation area to help preserve and restore the
amounts of water steam and other natural resources               vibrant plant life in this country the space is divided
during the last few years we have collaborated with                into three areas that focus on education reforestation
external partners to develop and test enhancements that             and preservation
have substantially improved the efficiency of the sites
                                                                   augusta georgia united states our manufacturing
processes to separate solids within the waste stream
                                                                    site manages a 650acre farm in burke county the
while enhancing its capability to handle highly variable
                                                                    facilitys wildlife habitat committee focuses on enhancing
feed input these innovations decreased water usage by
                                                                    biodiversity at the site through the implementation of
143 million liters per year about 10 percent of the total
                                                                    its wildlife management plan
usage for the site while reducing steam by 7000 metric
tons 5 percent of overall use at the facility these              clinton indiana united states in early 2011 we
changes saved more than 560000 in 2012 and projected             introduced a project that will showcase the compatibility
waste stream reductions related to the initiative could             of conservation and farming while protecting more
push annual savings to 2 million                                  than 300 acres at our manufacturing facility in this
                                                                    location a conservation easement will forever protect
biodiversity                                                        this land
lilly has a long history of working collaboratively to            we believe that lilly operations have limited impact
protect habitat and reduce the impact of our operations           on biodiversity for example we have commissioned a
on ecosystems we pursue a decentralized approach                longterm study of kinsale harbour near our manufacturing
recognizing that biodiversity challenges and opportunities        site in southern ireland this study ongoing since 1978
vary based on location and we engage in conservation             has suggested that the minor changes observed in the
projects and habitat enhancements at many sites                   aquatic life of kinsale harbour are associated with natural
worldwide we also support conservation efforts in the            stresses such as storm events rather than any discharge
communities where our facilities are located                     effects from our facility overall the harbors ecologic
                                                                  system has shown high resilience and an ability to
                                                                  thoroughly handle wastewater discharges




     54              lilly 20112012 corporate responsibility update

                                                                                                         fostering environmental sustainability

                     01          02          03          04            05        06          07          08          09




environmental compliance                                          during routine inspections in 2006 and 2007 the us                      environmental awards
                                                                  environmental protection agency identified potential                       and recognition
lillys policy is to comply with applicable health safety
                                                                  weaknesses in our leak detection and repair program at
and environment regulations wherever we do business
                                                                  our lilly technology center facility in indianapolis indiana
we believe compliance is foundational in maintaining our
                                                                  in addition in 2006 we voluntarily reported to the state
facilities righttooperate in their local communities
                                                                  and city environmental agencies that we had exceeded an
see page 47 for more information about our hse policies
                                                                  annual limit for air emissions in response to these events
standards and management systems if it is determined
                                                                  we have implemented numerous corrective actions and
that we are out of compliance we work to remedy the
                                                                  enhancements to our environmental programs we paid
situation as quickly as possible
                                                                  a penalty of 337500 in early 2011 to settle the case
we use environmental capability assessments to                    there was no harm done to employees neighbors or the                     listed as the 66th greenest us company 2011
apply statistical processcontrol techniques to our key           environment as a result of these events
environmental compliancerelated processes to reduce
                                                                  see the summary data table on page 56 for detail
the number of permit exceedances




                                                                                                                                             recognition of carbonmanagement programs for
                                                                                                                                             united kingdom operations 2011




                                                                                                                                             wildlife at work certification 2010




     55              lilly 20112012 corporate responsibility update

                                                                                                                             fostering environmental sustainability

                            01           02              03         04         05             06              07             08             09




                                                                                         23 24
fostering environmental sustainability summary data table

                                                                                      2007            2008           2009           2010           2011
energy use
energy consumption million btus                                              12900000     11900000       11300000     11200000    10800000
energy intensity thousand btussquare foot                                           594             562            543            520            495
energy intensity million btusmillion  revenue                                      692             584            517            485            470
direct energy consumption million btus                                        4670000         4510000     4230000      4190000     4370000
  coal million btus                                                           1410000         1290000     1140000      1280000     1170000
  natural gas million btus                                                    2480000         2400000     2400000      2200000     2300000
  fuel oil million btus                                                           768000        801000         661000        687000        459000
  liquid propane million btus                                                      18600         21500          29600         22700         15900
indirect energy consumption million btus                                      8240000         7360000     7120000      7000000     6860000
  purchased electricity million btus                                          4630000         4500000     4350000      4310000     4180000
  purchased steam million btus                                                2990000         2610000     2310000      2200000     2240000
  purchased chilled water million btus                                            619000        254000         449000        491000        445000

greenhouse gas emissions
greenhouse gas emissions scope 1 and scope 2 metric tons co2e               1810000         1730000     1640000      1600000     1530000
  scope 1                                                                           502000        483000         468000        452000        410000
  scope 2                                                                       1310000         1250000     1170000      1150000     1120000
greenhouse gas emissions intensity metric tons co2e1000 square feet                833            822           782           745           700
greenhouse gas emissions intensity metric tons co2emillion  revenue                971            851           752           695           630
scope 3 emissions not included in metrics above   25


  employee business travel personal car taxi rental car rail                    65000         65000          63000         72000         67000
  and air travel metric tons co2e                                                                                                                       23
                                                                                                                                                                some segments do not add up to totals due to rounding
  employee commuting metric tons co2e                                              76000         76000          76000         72000         71000   24
                                                                                                                                                                energy use greenhouse gas emissions except scope 3 and wateruse data
                                                                                                                                                                are reported on an adjusted basis accounting for mergers acquisitions and
  product transportation and distribution contracted metric tons co2e            30000         26000          39000         43000         50000        divestitures the other data in this table are nonadjusted
  waste generated in operations metric tons co2e                                   15000         14000          11000         17000         20000   25
                                                                                                                                                                these data do not include salesforce travel using company vehicles use
                                                                                                                                                                of lilly aircraft or product distribution with lilly vehicles those items are
  nonkyoto compound emissions refrigerants vocs etc metric tons co2e         14000         33000          15000         23000         54000        scope 1 and included in the data above




      56                    lilly 20112012 corporate responsibility update

                                                                                                                            fostering environmental sustainability

                             01          02          03          04            05             06             07             08             09




                                                                                      2007           2008           2009           2010           2011
water use
water intake billion liters26                                                        196           176           132           128           133
  municipal billion liters                                                                                                         65            66
  surface billion liters                                                                                                            0              0
  groundwater billion liters                                                                                                       63            68
water intensity million litersmillion  revenue                                     105          0864          0605          0555          0549

waste
waste generation metric tons                                                      379000        387000        287000        228000        242000
  hazardous waste generation metric tons                                           53800         55500         46400         31000         22000
  nonhazardous waste generation metric tons                                      325000        331000        241000        197000        220000
waste generation intensity metric tonsmillion  revenue                             203           190           131           988           107
waste disposition
  beneficially reused metric tons                                                 253900        198700        201600        148800        176200
  recycled includes incineration with energy recovery metric tons                31500        102000         28800         45000         35500
  treated includes incineration without energy recovery metric tons              49100         49700         35600         12300         13300   26
                                                                                                                                                               water intake as used in evaluating our progress toward our waterreduction
                                                                                                                                                               goal is the total amount of water coming into a facility including water
  landfilled metric tons                                                           44700         32600         21200         22100         17000        pumped from bodies of surface water and groundwater and water provided
                                                                                                                                                               by a utility it includes water used in processes utilities and other ancil
  landfilled related to goal metric tons27
                                                                                     32000         22300         14800         15900         10900        lary operations such as irrigation the term does not include groundwater
                                                                                                                                                               pumped solely for treatment to satisfy regulatory actions or requirements
                                                                                                                                                               eg remediation activities where the water is not used for another purpose
other air emissions                                                                                                                                            values do not include the water extracted from wells solely for the purpose
volatile organic compound emissions metric tons                                      526            560            549            626            735         of lowering the groundwater tables to maintain the physical and structural
                                                                                                                                                               integrity of building foundations data for breakdown of water intake by source
particulate matter metric tons                                                       311            293            384            200            146         are not available prior to 2010 water intake values for 2010 were adjusted from
                                                                                                                                                               previously reported values due to metering data evaluations at one of our top
so2 emissions metric tons                                                           3137          3188          2589          2015          1160        water use sites
nox emissions metric tons                                                           1205          1322          1125           877            798
                                                                                                                                                          27
                                                                                                                                                               our former and current wastetolandfill goals do not include construction
                                                                                                                                                               and demolition debris biosolids from wastewater treatment plants incinera
ozonedepleting substances potential kg cfc11 equivalent                            795           2376           749            790           3630        tor ash coal ash if reused for mine reclamation or road base and mycelia and
                                                                                                                                                               urea reused for fertilizer
                                                                                                                                                          28
                                                                                                                                                               reportable permitlimit exceedances are environmental releases to air
environmental compliance                                                                                                                                       water or land outside of regulatory limits these do not necessarily result in
reportable permitlimit exceedances28                                                   43             27             16             11              8         harm to people or the environment
                                                                                                                                                          29
                                                                                                                                                               significant spill in this report refers to any unexpected unintended abnor
number of significant spills      29
                                                                                         0              0              0              0              0         mal or unapproved dumping leakage drainage seepage discharge or
                                                                                                                                                               other loss of a substance that resulted in damage to the environment ie
environmental fines paid                                                         96900            0         12000        1200    34000030          human health aquatic life or wildlife or a material event requiring reporting
                                                                                                                                                               to the us securities and exchange commission damage means the actual
                                                                                                                                                               or imminent alteration of the environment so as to render the environment
energy waste and natural resource reduction fund                                                                                                             harmful detrimental or injurious
expenditures  millions                                                               0            65           57           41           08   30
                                                                                                                                                               see page 55 for detail




       57                    lilly 20112012 corporate responsibility update

                          lorem ipsum                                                                                                    united nations global compact index

                          01            02           03            04            05           06               07       08               09




united nations global compact index

ungc principles                                                                                                                               location in report

principle 1 b
              usinesses should support and respect the protection of internationally proclaimed human rights                                managing our supply chain pages 1011

principle 2 businesses should make sure they are not complicit in human rights abuses                                                       managing our supply chain pages 1011

principle 3 businesses should uphold the freedom of association and the effective recognition of the right to collective bargaining        supporting strong workplace practices page 31

principle 4 businesses should uphold the elimination of all forms of forced and compulsory labour                                           managing our supply chain pages 1011

principle 5 businesses should uphold the effective abolition of child labour                                                                managing our supply chain pages 1011

principle 6 businesses should uphold the elimination of discrimination in respect of employment and occupation                              diversity and inclusion pages 3435

principle 7 businesses should support a precautionary approach to environmental challenges                                                 fostering environmental sustainability pages 4457

principle 8 businesses should undertake initiatives to promote greater environmental responsibility                                         fostering environmental sustainability pages 4457

principle 9 businesses should encourage the development and diffusion of environmentally friendly technologies                             fostering environmental sustainability pages 4457

principle 10 businesses should work against corruption in all its forms including extortion and bribery                                  conducting our business ethically and transparently pages 0709




      58                  lilly 20112012 corporate responsibility update

                      lorem ipsum                                                                                      about this report

                      01          02          03          04            05         06           07           08        09




about this report
this is eli lilly and companys 20112012 corporate                the content and data in this report have not been
responsibility update this report highlights progress             externally verified lilly follows structured processes
and initiatives since our 2010 corporate responsibility            to collect evaluate and calculate the data we report
report it also serves as lillys annual communication on          to ensure appropriateness and accuracy we consider
progress for the united nations global compact ungc             external standards in deciding what data to collect and
of which lilly is a signatory the ungc is a strategic policy      report for example following guidance from the world
initiative for businesses that are committed to aligning           resources institute we report progress toward envi
their operations and strategies with 10 universally                ronmental goals on an adjusted basis accounting for
accepted principles in the areas of human rights labor           mergers acquisitions and divestitures as appropriate
the environment and anticorruption an index to the              to ensure comparability unless stated otherwise our
ungc indicators in this report can be found on page 58            global health safety and environment management
more information about the ungc can be found at                   system is certified by an independent accredited auditor
wwwunglobalcompactorg                                           in accordance with the american chemistry councils
                                                                   responsible care management system requirements
data and other updates contained in this report are
focused on the 2011 calendar year and include global               we welcome feedback on this report as it helps us
operations unless otherwise noted we also discuss                to improve future reports please contact
data and trends from previous years where relevant
and include some significant events and initiatives that           robert smith
occurred in the first half of 2012 this report does not           senior director corporate responsibility and
include joint ventures partially owned subsidiaries              president of the eli lilly and company foundation
leased facilities or outsourced operations
                                                                   email                         phone
our financial information which is prepared according             robsmithlillycom             3172762000
to the generally accepted accounting principles gaap
in the united states is subject to our own internal
accounting control systems and to external thirdparty
audits all dollar amounts given are in us dollars




     59               lilly 20112012 corporate responsibility update

wwwlillycom
